Chromatin remodeler Activity-Dependent Neuroprotective Protein (ADNP) contributes to syndromic autism

D’Incal, Claudio Peter; Van Rossem, Kirsten Esther; De Man, Kevin; Konings, Anthony; Van Dijck, Anke; Rizzuti, Ludovico; Vitriolo, Alessandro; Testa, Giuseppe; Gozes, Illana; Vanden Berghe, Wim; Kooy, R. Frank

doi:10.1186/s13148-023-01450-8

Review
Open access
Published: 21 March 2023

Chromatin remodeler Activity-Dependent Neuroprotective Protein (ADNP) contributes to syndromic autism

Clinical Epigenetics volume 15, Article number: 45 (2023) Cite this article

4514 Accesses
10 Citations
7 Altmetric
Metrics details

This article has been updated

Abstract

Background

Individuals affected with autism often suffer additional co-morbidities such as intellectual disability. The genes contributing to autism cluster on a relatively limited number of cellular pathways, including chromatin remodeling. However, limited information is available on how mutations in single genes can result in such pleiotropic clinical features in affected individuals. In this review, we summarize available information on one of the most frequently mutated genes in syndromic autism the Activity-Dependent Neuroprotective Protein (ADNP).

Results

Heterozygous and predicted loss-of-function ADNP mutations in individuals inevitably result in the clinical presentation with the Helsmoortel–Van der Aa syndrome, a frequent form of syndromic autism. ADNP, a zinc finger DNA-binding protein has a role in chromatin remodeling: The protein is associated with the pericentromeric protein HP1, the SWI/SNF core complex protein BRG1, and other members of this chromatin remodeling complex and, in murine stem cells, with the chromodomain helicase CHD4 in a ChAHP complex. ADNP has recently been shown to possess R-loop processing activity. In addition, many additional functions, for instance, in association with cytoskeletal proteins have been linked to ADNP.

Conclusions

We here present an integrated evaluation of all current aspects of gene function and evaluate how abnormalities in chromatin remodeling might relate to the pleiotropic clinical presentation in individual“s” with Helsmoortel–Van der Aa syndrome.

Introduction

Autism is a devastating condition, diagnosed in early childhood and characterized by qualitative impairments in social interaction and communication skills, accompanied by repetitive and stereotypic behaviors and interests [1]. Interestingly, recent advances in next-generation sequencing allowed large-scale exome sequencing initiatives revealing identification of a large series of genes involved in the disorder [2,3,4]. While collectively common, mutations in individual genes are rare and, in many cases, only a handful of patients with mutations in any specific gene are identified. Despite the genetic heterogeneity, the genes involved in autism converge on a limited number of biological pathways, including chromatin remodeling [5,6,7]. Genes involved in chromatin remodeling essentially encode for proteins which have a catalytic function in installing posttranslational histone modifications and DNA modifications (writers), removing such modifications (erasers) or have chromatin remodeling activity (remodelers) [8]. In this review, we discuss the multiple chromatin remodeling properties of the Activity-Dependent Neuroprotective Protein (ADNP) [9]. The ADNP gene has been found to be mutated in significant percentage of patients diagnosed with syndromic autism or intellectual disability and is one of its more frequent genetic causes [2,3,4, 10]. With the expansion of recent studies on the ADNP gene and its role in development, a comprehensive review of the function with emphasis on chromatin remodeling is warranted. Here, we provide an overview of what is known about the ADNP gene function since its discovery in 1999 till today.

ADNP is an embryonic gene essential for brain formation

The ADNP gene was first discovered as a vasoactive intestinal peptide (VIP)-responsive gene [9]. VIP is active during embryonic development and prevents neuronal cell death by inducing secretion of glia-derived survival-promoting factors. ADNP exerts a critical neuroprotective function, being essential for neural tube formation [11] and modulating its own gene expression [12]. The biological role of ADNP was associated with essential functions such as organogenesis of the developing embryo and proper brain formation [11]. Initial observations of Adnp haploinsufficient mice suggested a critical role in behavior with a major impact on cognitive function [13].

Spanning about 40 kb of DNA, the ADNP gene maps to the chromosomal position chr20q13.13 in the human genome and is comprised of five exons [10, 14]. Several splice variants have been described of which the longest transcript is 6672 bp ([14]; NCBI; NM_001282531.3) with the other variants all differ in the 5’ untranslated region (UTR). The last three exons are common to all transcription variants and translated into functional ADNP protein (Fig. 1A). Of note, an antisense transcript ADNP-AS1 has been annotated that is transcribed starting from ADNP exon 1 in the opposite direction. Whether it has any anti-sense activity remains to be determined. The ADNP protein consists of 1102 amino acids with a calculated molecular mass of 124 kDa [10, 14]. Spanning amino acids 74–686, nine C₂H₂-type zinc fingers were identified, to aid the protein in nucleotide binding in companion with the DNA-binding homeobox domain, located over amino acids 754–814. ADNP also encloses a glutaredoxin active site over position 220–243, which could potentially modulate its own DNA-binding activity or other DNA-binding proteins in response to oxidative stress and signal transduction pathways involved in the redox state of the cell [14, 15]. The neuroprotective function of ADNP is attributed to the octapeptide NAP sequence (NAPVSIPQ = Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln) ranging from the sequence 354 to 361 [9, 16,17,18]. An immunoprecipitation assay demonstrated the interaction between ADNP and eukaryotic translation initiation factor 4E (eIF-4E) by two putative binding motif sequences on the ADNP amino acid sequence 490—499, namely KclYcnyLp and cekYkpgVLL [19]. The presence of the bipartite nuclear localization signal (NLS) spanning amino acids 716–733 accounts for transport to the nucleus [14, 20]. Moreover, ADNP comprises both an alanine–arginine–lysine–serine (ARKS) motif located within the homeobox domain and a proline–valine–leucine (PxVxL) motif at position 819–823, which render ADNP the possibility to interact with heterochromatin protein 1 (HP1) [12, 21]. The ARKS motif functions in the stabilization of the interplay of HP1 and the PxVxL motif [21] (Fig. 1B). Together, both motifs are involved in HP1-dependent H3 lysine 9 trimethylation (H3K9me3) association and localization to pericentromeric heterochromatin [21]. In this respect, multiple WD repeat-containing protein 5 (WDR5) that mediate the assembly of histone modification complexes were discovered on ADNP, tying it also to the WDR5-interacting protein Sirtuin 1 (SIRT1) [22]. Moreover, ADNP was also shown to interact with the autophagy-initiating protein microtubule-associated protein 1 light chain 3 (LC3) by direct immunoprecipitation and presents with LC3-binding sites covered all over the protein [23]. Most recently, a linear motif prediction mapped multiple Src homology 3 (SH3) domain-ligand association sites in ADNP, surprisingly one in the NAP sequence, suggesting a regulatory role of the cytoskeleton [24]. Remarkably, these SH3-binding site are essential to the autism-mutated SH3 and multiple ankyrin repeat domains protein 3 (SHANK3) protein. Using actin-immobilized beads, ADNP and SHANK3 were found to be co-immunoprecipitated, thereby linking a functional role of ADNP binding by its NAP domain via the cytoskeleton with SHANK3.

ADNP is expressed in many tissues with the highest expression in different regions of the human brain, gastrointestinal tissues, lungs, and reproductive system. Moderate expression is observed in the kidneys, smooth muscles, and soft tissues, and low to absent levels in cardiac muscles, adipose tissue, liver, and skeletal muscles [14] (Fig. 2A). During mouse development, ADNP shows a high expression, peaking at embryonic days 9–13, concomitant with neural tube closure, in the entire embryo, while brain expression is sustained into later stages of development [11]. Predominant expression of ADNP is observed in the hippocampus, cortex, and cerebellum [12, 25].

An initial study reported the expression of exogenous ADNP-GFP transfected in HEK293T cells restricted to the nucleus [12]. Human recombinant ADNP was shown to colocalize with defined DAPI-positive foci in the nucleus in vitro. Nuclear DAPI foci have been described to correlate with heterochromatin densities, and the presence of ANDP is such foci were a first lead that the protein can be involved in chromatin remodeling [26]. In the P19 pluripotent teratocarcinoma cell line, ADNP expression was restricted to the nucleus in non-differentiated pluripotent cells and DMSO-differentiated cardiovascular cells [27]. However, following retinoic acid-induced differentiation of P19 pluripotent cells into neuronal cell types, ADNP expression was detectable in the nucleus as well as in the cytoplasm and neuronal extensions in cultured neurites. A nuclear export mechanism has not been formally explained, but is predicted based on some similarity of the leucine-rich nuclear export sequence of chicken engrailed protein 2 (En2) with aa 788–804 ADNP sequence [14, 28], but this observation awaits experimental validation. ADNP expression in other cell types including mouse heart and placenta remained restricted to the nucleus. In rat brain expression was mainly observed in the cytoplasm of neurons and its dendritic extensions signals using immunoreactivity [29]. Occasionally, weak signals indicated a partial nuclear localization in these neurons. In contrast, rat astrocytes showed nuclear and an (almost) absolute lack of cytoplasmatic expression. In rat cortical astrocyte cultures, ADNP was found in the nucleus as well as in the cytoplasm, but also reported in the culture medium, suggesting secretion of the protein [30]. In the astrocyte cytoplasm, ADNP colocalized with tubulin and microtubules, but not with actin filaments, indicating a potential crosstalk of ADNP with the cytoskeleton [30].

In transfection assays in HEK293T cells, wild-type ADNP was reported in the nucleus of transfected [20]. When patient mutations in ADNP were modeled in this cellular system, a marked effect on expression and subcellular localization was observed depending on their position in the protein. Mutations at the C-terminal side of the NLS were expressed in the nucleus, similar to wild-type ADNP. Mutations in the central region of ADNP that result in a truncated protein lacking the NLS sequence were mislocalized in the cytoplasm. As mutations approached the N-terminus, ADNP expression was absent or at least undetectable since these short fragments undergo ubiquitination and are prone to proteasomal decay.

Genome editing (CRISPR/Cas9) in N1E-115 neuroblastoma cells to form neuron-like cell lines expressing ADNP-mutant proteins conjugated to GFP indicated distinct cellular phenotypes depending on the mutation location [31]. Truncating mutation close to the N-terminus showing increased neurite numbers in non-differentiated cells followed by increased neurite lengths upon differentiation. In contrast, a mutation destroying the NLS showed decreased cell numbers in non-differentiated cells. Both mutant proteins showed elevated expression in the cytoplasm compared to the non-mutated GFP-ADNP. Reduced nuclear/cytoplasmic boundaries were observed with both mutations, but most notably in the NLS-truncated ADNP-mutant line. Recently, the subcellular localization of Adnp was investigated in somatosensory-derived primary neurons, where Adnp was visualized in the nucleus of undifferentiated neurospheres but showed a remarked cytoplasmic shift in differentiated cortical neurons after neuritogenesis [32]. Moreover, co-immunoprecipitation experiments demonstrated binding of Adnp to several 14-3-3 protein isoforms with a well-known function in nuclear-cytoplasmic protein localization. Also, administration of the 14-3-3 inhibitor difopein restricted Adnp expression solely to the nucleus, thereby indicating that Adnp shuttles to the cytoplasm by the 14-3-3 nucleocytoplasmic shuttling protein.

Together, these findings indicate a developmental, cell, tissue, and mutation-specific expression of ADNP, suggesting a multimodal function of the protein in health and disease.

ADNP is a highly conserved chordate-specific gene that only shows homology with its paralogue Activity-Dependent Neuroprotective 2 gene (ADNP2)

The original cloning of human ADNP identified a single paralogous sequence in the human genome later named Activity-Dependent Neuroprotective Protein 2 (ADNP2) [14, 33]. The sequence of human ADNP and ADNP2 shows 33% identity and 46% similarity. The genomic structure of the human ADNP2 gene resembles that of ADNP, but contains only 4 exons, lacking a paralogue of the non-coding exon 2 (Fig. 1A) [14, 34]. The ADNP2 protein is estimated to be 1131 amino acids long with a theoretical molecular weight of 122.8 kDa (https://www.uniprot.org/). Based on the presence of putative zinc fingers and homeobox domain, ADNP2 has a suggested function in cell signaling, cell structure and motility and chromatin remodeling. A monopartite NLS sequence VPFKRQRNE starting from amino acid position 1015–1023 was predicted by the cNLS Mapper motif prediction program [34, 35] (Fig. 1B). Overall, the expression pattern of ADNP2 resembles that of ADNP, showing a high expression in tissues such as the cortex and cerebellum. Other tissues such as the heart, kidneys, and uterus were reported with a moderate expression. Low expression levels are observed in the testis, pancreas, spleen, liver, lungs, and skeletal muscles [33] (Fig. 2B). Interestingly, ADNP2 also showed a high expression in utero at E7.5, two days before the expression peak of its paralogue ADNP at E9.5, suggesting a crucial role in development, formation, and function of the brain [11, 33]. In search for ADNP2 function in vivo using a zebrafish model let to the discovery of an evolutionary conserved role for the ADNP protein family, essential for erythropoiesis [34]. Both ADNP and ADNP2 were discovered to regulate beta-globin, both interacting with BRG1, a key chromatin remodeling SWI/SNF component, and with ADNP directly interacting with the beta-globin locus control region.

ADNP in neurodevelopment

ADNP mRNA is enriched in the mouse brain (hippocampus, cerebellum), in comparison with peripheral tissues, implicating an important role for ADNP in brain functioning [9]. Mouse embryonic ADNP mRNA reaches its maximum expression level at E9.5, when cranial neural tube closure takes place [11]. After E14.5, ADNP expression decreases in the whole embryo but was sustained in the embryonic brain. In Adnp knockout (KO) mouse embryos that show lethal defects in brain formation and neural tube closure, Oct4 expression was upregulated, while Pax6 expression was downregulated and even absent in the anterior neural plate [11]. Pax6 plays an important role in the development of the central nervous system and defects in Pax6 expression can cause, for example, microcephaly [36], which was originally associated with the ADNP-regulator VIP functional deficiency [37]. Further observations looking at Adnp knockout embryos suggested generally inhibited development (smaller embryos). In P19-cell-derived neurons, ADNP inhibition resulted in a reduced neurite number [27], paralleling the effect observed following a downregulation of the SWI/SNF (BAF) complex [reviewed in 38]. In line with these observations, Adnp KO mESCs were not able to form organized embryoid bodies and showed downregulation of neuroectodermal genes, including Pax6 and Nestin. Differentiated neural progenitor cells (NPC) from Adnp KO mESCs showed downregulation of Nestin, and only 31% was Pax6 positive, compared to the control NPCs with a 60% Pax6 positivity rate. At day 19 of differentiation, the Adnp KO mESCs showed less neuronal fibers and reduced TuJ1 and GFAP signals. RNA-seq at different time points during differentiation showed that neuroectodermal genes were downregulated, while pluripotency and primitive endodermal markers were upregulated in Adnp KO mESCs. These defects could partially be rescued when ADNP expression was restored in an early stage, again stressing the role of ADNP in neural development [39]. Along the same line, the observed ADNP regulation [40] and interaction with components of the Wnt/β-catenin pathway [41] further support its critical involvement in neural development [42]. More recently, ADNP was found to interact through its N-terminus with the armadillo domain of β-catenin, thereby stabilizing the protein, and protect it from hyperphosphorylation and degradation [41].

Mutations in ADNP result in Helsmoortel–Van der Aa syndrome (HVDAS)

Genome-wide whole-exome studies in patients with autism co-morbid with intellectual disability (ID) revealed an excess of truncating de novo mutations in the ADNP gene is (p = 0.001852, odds ratio = 13.24668, one—sided Fisher’s exact test) [10, 43]. In an initial study, 10 individuals with a syndromic version of autism were described. In subsequent screening studies using whole-exome or molecular inversion probes in large cohorts of patients with ID and or autism in large cohorts of thousands of patients, ADNP is consequently among the most frequently mutated genes observed [2,3,4, 44]. In a later study, the clinical presentation of 78 individuals all with a loss-of-function mutation in ADNP was compared [45]. All patients had developmental delay, ID, mostly moderate to severe, and the greater majority of 93% had autism or autistic features. Individuals with ADNP disruptions were reported to have a less severe social affect symptoms compared to other monogenetic or idiopathic forms of autism. In the ADNP individuals, verbal intelligence explained to some extend the variance in social impairment [46, 47]. Behaviors in this group of 11 individuals with an ADNP mutations were characterized by high levels of stereotyped motor behaviors. Furthermore, within the ADNP group, age of walking predicted cognitive outcomes. A syndrome-specific sensory reactivity symptoms phenotype was identified, characterized by high levels of sensory seeking across tactile, auditory, and visual domains irrespective of age, sex, degree of autism, IQ, and adaptive behavior in a in an independent cohort of 22 affected individuals [48]. Additionally, using the Vineland Adaptive Behavior Scale, in a smaller cohort of 4 patients, implicated age-dependent developmental delays with increased impact of activities of daily living coupled to possible early neurodegeneration [46, 47]. Dysmorphic features included but were not limited to a prominent forehead with high anterior hairline, wide and depressed nasal bridge, and short nose with full, upturned nasal tip. More than 50% of patients suffered also from feeding and gastrointestinal problems, from visual problems, showed abnormal behavior, suffered from sleep problems, had hand or foot abnormalities, had brain abnormalities including seizures, had musculoskeletal issues such as scoliosis, joint laxity, and hip dysplasia, and was highly sensitive to infections of any kind [45; Table 1]. Apart from such frequent condition, a large minority of individuals with an ADNP mutations also suffered from congenital heart disease, ear–nose–throat system dysfunction, short stature, and abnormalities of the endocrine system. Of note, primary tooth eruption has been reported as accelerated [40]. The Helsmoortel–Van der Aa syndrome (OMIM # 615,873) can thus best be summarized as a complex neurological disorder that affects a multitude of organs and tissues [45, 49]. A permanently updated version of the clinical symptoms of the disorder can be found at the human disease genes website (https://humandiseasegenes.nl/adnp/). [50]

Table 1 Clinical features of individuals with a mutation in the ADNP gene

Full size table

So far, only loss-of-function mutations such as stop-gain or frameshift mutations have been reported as unambiguously causative. Most, but not all mutations might give rise to a truncated protein [45, 51]. A single individual with a deletion of one copy of the entire ADNP gene has been described and the clinical presentation of this individual overlaps with those of loss-of-function mutations. The latter suggests that the Helsmoortel–Van der Aa syndrome could be due to a loss-of-function mechanism. However, as many mutations cluster in the fifth and last exon and escape from NMD has been demonstrated, the majority of patients might still produce protein. Thought it needs to be mentioned that mutated protein has never been unambiguously demonstrated in patients, an additional gain of toxic function of the mutant protein, if present, could also be envisaged [31, 51, 52].

The majority of mutations are unique and only observed in a single individual, so far. However, a few mutations, such as the p.Tyr719*, p.Arg730*, and p.Asn832Lysfs*81, are recurrent. Interestingly, patients with a p.Tyr719* mutation started to walk independently at a significantly later age had a higher pain threshold [45].

The role of mosaicism in patients

The broad diversity of clinical presentations in some, but not all ADNP-mutant individuals is yet unexplained. That ADNP mutations arise as de novo mutations, where neither parent appears to have the mutation in their blood, begs the question as to how and when these de novo mutations arose. De novo mutations can arise in the germline, the developing embryo, fetus, child, or postnatally, throughout aging [reviewed in 53]. De novo mutations may present mosaically, with different mutation loads in different tissues. Such variations may vary among ADNP-mutant individuals. There are several studies of inter-tissue mosaicism of de novo mutations [54, 55]. A proper study of de novo mutations requires both access to multiple tissues and a sensitive quantitative means of mutation loads assessment [54]. Variable levels of mutation loads between affected and non-affected organs/tissues might explain the heterogeneous clinical spectrum of ADNP-affected individuals, as well as many de novo mutated ASDs.

Opposing epigenetic signatures of the Helsmoortel–Van der Aa syndrome

Over the last years, methylation signatures specific for a series of neurodevelopmental disorders caused by mutations in a diverse series of genes have been identified [56]. When analyzing individuals with an ADNP mutation, uniquely two different and in part opposite methylation patterns were observed, depending on the location of the mutation in the gene. Mutations in the first half of the gene and mutations near the C-terminus of the protein result in a general pattern of approximately 6000 hypomethylated CpGs, whereas mutations in the central region of the gene resulted in a more limited set of approximately 1000 hypermethylated CpGs [57, 58]. It should be noted that no mutations in the intermediate region of the gene between aa 430 and 719 have been analyzed. Such methylation patterns established in patients with mutations in ADNP and showing confirmed symptoms of the Helsmoortel–Van der Aa syndrome have been postulated to be of value in determining the causality of apparent missense variants of unclear medical significance [59]. Of the six variants analyzed, only one de novo variant c.201G > C affecting the last nucleotide of ADNP exon 4 and predicted to affect splicing showed a methylation pattern consistent with the epimutations caused by loss-of-function mutations in the first half of the gene, suggesting that some missense mutation may not result in Helsmoortel–Van der Aa syndrome [57]. Unexpectedly, transcriptome analysis in blood cells did not identify clear differences between the two types of episignatures and a clear genotype–phenotype correlation between patients of either episignature was not identified [57, 58]. Interestingly, distinct phenotypes were associated with two mutations reflecting the different episignatures in cell culture [31], in line of a more severe phenotype observed in patients with the p.Tyr719* mutation (Box 1).

Box 1 Western blot detection of ADNP

Full size table

ADNP interacts with multiple chromatin remodeling proteins complexes

Chromatin structure is determined by a dynamic interplay between the DNA and cellular proteins. It can be modified by various mechanisms, including ATP-dependent chromatin remodeling (see Box 2) (Fig. 3A). Multiple studies have revealed an interaction between ADNP and members of different chromatin remodeling complexes. Accordingly, ADNP depletion leads to changes in chromatin structure and epigenetic variation in gene expression [39, 63,63,65]. However, the exact nature of the interactions between ADNP and proteins of different types of chromatin remodeling complexes remains ambiguous and five partially complementary theories have been put forward (Fig. 3).

Box 2 Chromatin remodeler complexes

Full size table

Interaction with SWI/SNF complex

Mandel and Gozes [12] demonstrated an interaction between ADNP and different proteins of the BAF chromatin remodeling complex. Human kidney HEK293T cells were transfected with recombinant ADNP fused to GFP at the N-terminus. Immunoprecipitation was performed with nuclear extracts using both anti-GFP and C-terminal ADNP antibodies which resulted in co-purification of ADNP among other binding proteins. However, C-terminal ANDP immunoprecipitation did not show binding partners, suggesting that the C-terminal part of ADNP is required for protein interaction. After size separation on polyacrylamide gels, additional protein bands were observed together with the 175 kDa GFP-ADNP fusion product. Mass spectrometry identified the BRG1, BAF250a, and BAF170 as co-precipitating with ADNP. The presence of these three subunits of the BAF complex, encoded by the SMARCA4, ARID1A, and SMARCC2 genes, respectively, was confirmed by Western blotting. Multiple co-immunoprecipitation experiments were performed, with antibodies against a recombinant ADNP, fused to a GFP-tag, and against endogenous BRG1, all confirming that ADNP interacted with BRG1, BAF250a, and BAF170. In cellular stainings, co-localization of ADNP and BRG1 was seen, implicating a nuclear anchoring of ADNP to the SWI/SNF chromatin remodeling complex (Fig. 3B).

ADNP is part of the ChAHP complex

Interaction of ADNP with the chromatin remodeler CHD4 and HP1 in a complex referred to as ChAHP was observed in ADNP-flagged mouse ESCs [39]. Binding with HP1 was previously reported during co-immunoprecipitation [63] and ChIP-seq experiments [72]. The study of Ostapcuk [39] showed that HP1γ was the most abundant isoform in the ChAHP complex, followed by HP1β. Interestingly, binding of the HP1α isoform was almost absent, whereas the study by Mandel [63] reported binding predominantly to HP1α. ADNP interacts with CHD4 through its N-terminus and with HP1β/γ through its C-terminus [39]. For this reason, it was speculated that HVDAS patients, who have C-terminal ADNP truncating mutations, could not form the ChAHP complex. Indeed, introduction of the most prevalent HVDAS mutation p.Tyr718* in the murine cells, mirroring the human p.Tyr719* mutation, retained binding to CHD4 but lost its ability to bind HP1. Since HP1 binds to H3K9me3, a silencing epigenetic mark common to pericentromeric regions, the HP1 might function to recruit its partners in the ChAHP complex to these repressive modifications. These findings confirmed earlier observations that ADNP binds the HP1-specific H3K9me3 histone mark in HeLa cells [21]. In the latter study, all three HP1 isoforms could act as a partner of ADNP in vitro but binding of ADNP could only be confirmed in mouse embryonic fibroblasts with the HP1α and β isoforms, suggesting the ADNP-HP1 interactions are influenced by additional cellular factors. Similarly, Ostapcuk found a ChAHP protein complex association between ADNP and CHD4 with H3K9me3-marked chromatin in mESCs. The ChAHP complex could still bind to its target genes when the chromodomain of HP1γ was mutated and binding of HP1γ to H3K9me3 was not altered in the absence of ADNP [39]. This suggested that ADNP recruits the ChAHP complex to specific sites in a sequence-specific manner. However, ADNP requires HP1 to repress gene transcription, which was shown upon generation of triple knockout cells for the three HP1 isoforms. These cells showed upregulation of specific genes that were also upregulated in the absence of ADNP only. These results are in line with ATAC-seq experiments revealing lack of ATAC-seq signals at ChAHP bound loci, suggesting that ChAHP is bound to non-accessible chromatin. In the absence of ADNP, these sites became accessible. Recently, an overlap in the peak spectrum of ADNP and CTCF sites was identified, indicating ChAHP-binding sites [65]. The absence of ADNP increased the CTCF signal, suggesting that ChAHP and CTCF compete for the same genomic binding sites (see below). By competition for CTCF sites, ChAHP reduces the accessibility of chromatin to prevent endodermal gene transcription in mESCs during neuroectodermal differentiation to ensure correct lineage specification. In the absence of ADNP, the ChAHP-binding sites became more accessible with neuronal progenitors expressing mesodermal markers instead of neuronal markers (Fig. 3C).

ADNP-BRG1-CHD4 (ABC) triplex

More recently and in part contrasting with earlier reports, ADNP was reported to bind both CHD4 by its N-terminus and BRG1 by its C-terminus in mESCs [64]. This interaction was found by performing immunoprecipitation of ADNP followed by mass spectrometry using N-terminal and C-terminal ADNP antibodies. Subsequent ChIP-seq analysis of ADNP compared to ChIP-seq data for BRG1 and CHD4 showed that all three proteins were localized in similar genomic regions, including promotor regions and intergenic regions. In total, 31% of peaks overlapped between the 3 proteins. In concordance with earlier work, ATAC-seq experiments showed that ADNP bound to inaccessible chromatin. Consequently, loss of ADNP showed more ATAC-seq signals, indicative for accessibility to chromatin. However, these signals where not only linked to ADNP-bound loci. Therefore, these results rather suggest that ADNP is able to control chromatin architecture through its interactions with other chromatin remodelers. Previous studies confirmed contribution of ADNP-interacting chromatin remodelers BRG1 and CHD4 to bivalent histone modifications [73, 74]. Alterations of bivalent histone modifications in developmental genes in mESCs have been discovered in ChIP-seq experiments in the H3K4me3 and H3K27me3 markers [64]. Loss of ADNP increased the ratio of these histone marks, with a significant increase in the expression of the H3K4me3 marker over the repressive H3K27me3 mark, thereby forcing transcription at key primitive endoderm (PrE) gene promotors of, for example, Gata6 and Sox7, resulting in prominent upregulation these genes and priming ESC differentiation toward endodermal cell types (Fig. 3D).

The nuclear ADNP-HP1-POGZ complex

The autism/ID-risk gene POGZ, in which pathogenic variants have been associated with the White–Sutton syndrome, has been reported to interact with HP1 [75]. By co-immunoprecipitation of nuclear extracts of the embryonic mouse cortex, POGZ was shown to bind with HP1γ, but not with HP1α. HP1γ was also found to bind ADNP and CHD4 to form the ChAHP complex, which suppressed gene transcription [39 see above]. Using the Cut&Run technique, occupation of mutual chromosomal loci of Pogz, HP1γ, and Adnp was detected in the mouse embryonic telencephalon [76]. Thousand consensus loci were found in common among these three proteins, and overall these were associated with euchromatin as indicated by an enrichment for H3K27ac, but not for H3K9me3 characteristic of heterochromatin. Next, the presence of Adnp was investigated at loci where Pogz promotes expression of neuronal genes. Interestingly, reduced co-occupation of both Adnp and HP1γ with Pogz was observed at loci near genes that were downregulated in homozygous Pogz knockout mice. The proposed mechanism of the ADNP-HP1-POGZ complex involves Pogz promoting transcription at sites with less Adnp/HP1y co-occupancy but acting as a transcriptional repressor at sites with high ADNP/HP1y co-occupancy. The dual role of Pogz reflected on gene expression in Pogz homozygous knockout mice, where high ADNP-HP1-POGZ levels caused an upregulation of proximal genes, whereas high POGZ levels together with reduced ADNP/HP1y levels caused gene downregulation (Fig. 3E).

ADNP-WDR5-SIRT1-BRG1-HDAC2 including YY1 complex

Most recently, several interactions sites of ADNP with SIRT1 were predicted, namely common interaction with WD repeat-containing protein 5 (WDR5), which mediates the assembly of histone modification complexes, as well as common interaction with BRG1 (see also above) and co-regulation by YY1 [22]. With common interaction partners and targeting of similar pathways such as TP53 and autophagy, the predicted ADNP-SIRT1 interaction was confirmed by immunocytochemistry in HEK293T cells and human iPSC-derived neurons. Moreover, immunoprecipitation experiments with EB1/EB3 antibodies in human neuroblastoma cells revealed co-elution of ADNP and SIRT1. However, in neuronal progenitor cells the EB1/3-SIRT1 interaction was initially lost but could be restored at low detection levels by administration of NAP, enhancing microtubule dynamics. Additionally, co-elution of Alzheimer protein Tau could be observed after EB1/EB3 immunoprecipitation, suggestive for a functional interaction of ADNP, SIRT1, and Tau, again enhanced after NAP administration. Mechanistically, exploring the promoter regions identified shared motifs among ADNP, YY1, BRG1 (SMARCA4), and HDAC2, with HDAC2 showing the highest similarity to ADNP (Fig. 3F).

ADNP regulates microtubule functions

Microtubules (MT) consist of long cytoskeletal cylinders of polymerized tubulin, which are important for axonal plasticity and brain development [77, 78, 79]. An association between ADNP and microtubules has been reported in multiple studies [e.g., 80, 77]. End-binding proteins (EB) interact with MT-binding proteins and are important for axonal outgrowth, axonal transport, and dendrite formation. There are three EB family members (EB1, EB2, and EB3) of which EB3 is most abundant in the brain but both EB1 and EB3 are expressed in neurons. The latter two proteins are important for microtubule growth and interact with the SxIP motif (SIP, Ser-Ile-Pro), present in proteins such as ADNP to bind to MT and affect MT dynamics [19, 81].

Tau, a MT-associated protein important for tubulin assembly and MT stabilization, binds EB3 and regulates the localization and function of EB1 and EB3 in neuronal cells [82,80,81,85]. Tau is broadly expressed in neurons and is associated with different neurodegenerative diseases, collectively called tauopathies, like Alzheimer disease [83]. Interestingly, somatic ADNP mutations are directly correlated with increased tauopathy in the AD brain [85] and tauopathy was discovered in postmortem HVDAS child brain [86] as well as in mouse models with either Adnp haploinsufficiency [13] or carrying the p.Tyr718* mutation (the human p.Tyr719* orthologue [52]). In cell model systems, MT growth track length, and growth track speed of EB3 in cells that expressed the ADNP mutations, was decreased in speed and track length of EB3 compared to expression of full-length ADNP. Interaction of Tau with MTs was attenuated in the mutated cell lines [24, 86].

Other links between ADNP and Tau include increased mRNA and protein levels in the tauopathy mouse model compared to the wild-type littermates until the age of three months [61]. At 5.5 months, the ADNP level decreased. Tau has multiple isoforms, like 3R and 4R, which have, respectively, three and four repeats of the tubulin-binding motif. The ratio between these two isoforms is 1:1 in normal human brain. (And in normal mature mouse brain, the 4R tau is enriched.) The 1:1 ratio is disturbed in frontotemporal dementia, as was also seen in the tauopathy mouse model used above. These mice had increased levels of 3R mRNA at the age of three months, which disappeared in 5.5-month-old mice, paralleling the decrease in ADNP mRNA levels. The transgenic overexpression of mutated 4R in the mouse model is induced by the tetracycline-operon-responsive element and can be suppressed by doxycycline. After treatment with doxycycline, both Tau 3R mRNA and ADNP mRNA and protein levels normalized at the age of three months. Parallel experiments suggested an involvement of ADNP with MAPT (encoding Tau) alternative splicing with ADNP interacting with BRM and polypyrimidine tract-binding protein (PTB)-associated splicing factor (PSF)-binding, with PSF being a direct regulator of Tau transcript splicing [61].

In an independent study, increased ADNP mRNA levels were observed in certain brain regions in a six-month-old AD mice model [87]. The brain regions with increased ADNP levels were the regions where also Aβ plaques accumulated, possibly driven by Aβ toxicity. However, the option that these abnormalities were driven by Tau pathology was not excluded. Seemingly, in line with these observations, there is an increase of ADNP mRNA in lymphocytes in AD patients, possibly as a compensatory mechanism. Furthermore, higher premorbid intelligence was associated with greater serum ADNP levels [88]. In agreement with the latter observation and in a search for potential biomarkers, ADNP was the only protein reported as downregulated in the serum of patients with Alzheimer’s disease [89].

Autism-mutated ADNP plays a pivotal role in autophagy by affecting cytoskeleton dynamics

Autophagy is a catabolic process via which superfluous or damaged proteins and organelles are delivered to the lysosome and degraded to release free amino acids into the cytoplasm. It is a highly conserved process, preserving cellular homeostasis by sequestering macromolecules and organelles into an autophagosome for delivery to a lysosome for degradation [90]. Subsequently, the degraded cargo containing nucleotides, peptides, and free fatty acids are released into the cytosol for metabolic reuse [91]. Defects in the autophagy pathway are associated in the pathophysiology of cancer, metabolic disorders, neurodevelopmental disorders as well as neurodegenerative diseases [92,90,91,95], and schizophrenia [23]. Several autophagy-related genes and proteins regulate the autophagy pathway, including Beclin 1 (BECN1), microtubule-associated protein 1 light chain 3 (LC3), and sequestosome 1/p62 (SQSTM1) [96]. BECN1 is responsible for autophagosome formation, while LC3 ensures maturation and closure of the autophagosome membrane. Moreover, LC3 is cleaved into LC3-I and the phosphatidylethanolamine conjugated LC3-II, which can be used as markers for the autophagy process. SQSTM1 ensures recognition of targets that are prone to autophagy by binding to ubiquitinated proteins, linking those to LC3 in the phagophore membrane [97]. In mice, ADNP has been shown to co-immunoprecipitate with LC3B after incubation with an ADNP antibody. The LC3B–ANDP interaction was partially lost in co-immunoprecipitation with brain extracts from Adnp^± mice [23]. Furthermore, Adnp haploinsufficiency reduced the expression of Becn1 in the hippocampus [23]. Remarkably, autophagy was reported to be sexually divergent in an Adnp haploinsufficient model. Whereas RNA sequencing revealed negligible expression levels of Becn1 in wild-type and Adnp heterozygous males, immunohistochemical studies identified a remarkable decrease in the expression of Becn1 in Adnp heterozygous females in comparison with female littermate controls. In addition, the expression of Becn1 could be differentiated between male and female mice, with females expressing a twofold higher hippocampal Becn1 cells compared to wild-type males [98,96,100]. Similarly, a postmortem brain study in a 7-year-old male patient carrying a de novo mutation in the ADNP gene (described above has presenting tauopathy) revealed a decreased expression of BECN1 in the cerebellum, mimicking the Becn1 downregulation in Adnp haploinsufficient mice [86]. Finally, in a novel mouse model of Adnp, carrying the p.Tyr718* point mutation mimicking the most common human ADNP mutation, p.Tyr719*, FOXO3 was discovered as a new target of ADNP specific gene expression regulation with both ADNP and FOXO3 interacting with LC3 interaction [52] as well as with SIRT1 [22]. These findings suggest an association of autophagy, the cytoskeleton, and autism with regard to interaction with ADNP.

ADNP and its regulating neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) protect neurons against stress

Oxidative stress is caused by an imbalance in reactive oxygen–nitrogen species (ROS/RNS) overproduction and detoxification. Excessive oxidative stress plays a major role in brain aging and other unfortunate conditions such as hypoxia. The production of these radical molecules is detrimental for cellular structures, since they are potent of chemical modifications of nucleic acids, lipids and proteins, thereby causing neuronal cell death [101]. Oxidative stress models induced with peroxide showed an increase pro-apoptotic protein p53. Treatment with human recombinant ADNP protected neurons against the induced oxidative stress in conjunction with reducing p53 levels, thereby correlating fluctuations in ADNP expression to cellular protection [102]. Similar to ADNP, the expression of sister paralogue ADNP2 also changed after peroxide administration in P19 embryonic cells. Silencing RNA-mediated knockdown of ADNP2 resulted in reduced oxidative stress associated cell viability, indicating that ADNP2 could play an essential role in cell survival pathways [33]. In addition, resistance to cell death was studied in malignant peripheral nerve sheath tumor (MPNST) cells, a lethal feature of patients suffering from neurofibromatosis type 1. Here, the neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) induced an upregulation of ADNP, associated with a decrease in p53 expression [103]. It should be noted that PACAP and VIP (cited above as an ADNP regulator) share sequence and functional homology, and both have been shown to regulate ADNP [104]. Furthermore, the original cloning of ADNP associated it with p53 regulation and with specific amplification and expression changes in cancer [14]. Thus, it was suggested that PACAP/ADNP signaling is involved in tumor cell survival through p53 modulation. In nutrient-rich cultures, administration of exogenous PACAP38 induced an increase in ADNP expression in MPNST cells, which was shown to be associated with enhanced resistance to peroxide-induced cell death, reduced p53 and caspase-3 expression, together with less DNA fragmentation. Moreover, deprivation of nutrients enhanced resistance to oxidative stress which could not be ameliorated upon PACAP38 administration. These results indicate that nutrition deficiency forces MPNST cells to adapt to cellular stress by activating PACAP-driven ADNP signaling [103]. In an independent study, PACAP was discovered to regulate the stress-signaling axis in a sex-dependent manner. For this study, Adnp wild-type and Adnp heterozygous mice were treated with PACAP38 and subjected to stressful situations. Male heterozygous Adnp mice were more responsive to stress than females in object and social recognition. However, heterozygous females were less adaptive to stress in the open field and elevated maze tests. Pre-treatment with PACAP38 normalized the stress-evoked behavior in Adnp deficient mice. Moreover, splenic Adnp expression and plasma cortisol levels were regulated in a sex- and genotype-dependent manner, both correlated with cognition in male mice and anxiety in both genotypes. These deficits could be corrected by PACAP treatment, positively correlating to plasma cortisol levels. These findings were further investigated in a cohort of young men, where ADNP expression was positively linked to stressful situations and high salivary cortisol levels. These findings suggest ADNP as a biomarker for stress response assessment [105].

The NAP motif in ADNP

NAP (Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln, single letter code, NAPVSIPQ also known as davunetide, AL-108 and CP201) was originally identified as the smallest, conserved neuroprotective motif of ADNP [9, 14, 25], including amino acid overlap with the previously discovered activity-dependent neurotrophic factor (ADNF) [106, 107].

NAP and microtubules

NAP associates with tubulin, a subunit protein of MTs, which are important for axonal plasticity and brain development [74, 77, 78, 79]. However, no interaction or influence of NAP on polymerization and dynamics of microtubules has been described [108]. The NAP structural similarity to cell penetrating peptides [77], coupled to proven dynamin-mediated endocytosis [109], also allows its binding to intracellular microtubule end-binding (EB1/3) proteins through its SxIP motif (NAPVSIPQ) [81]. ADNP mutations occur significantly more in AD brain than in control brains, and the effect of the mutations on microtubules was studied by growth track length, and growth track speed of EB3. In cells expressing the ADNP mutants, a decrease in speed and track length of EB3 compared to expression of full-length ADNP was observed. Treatment with NAP restored the tested parameters, while interaction of Tau with MTs was attenuated in the mutated cell lines. Furthermore, the MT-NAP interaction is associated with protection against autophagic deficits, with ADNP binding to microtubule-associated protein 1 light chain 3 (LC3) augmented by NAP (described above) [23, 98, 100, 110, 111]. In this respect, NAP partly corrects RNA transcript expression levels that are deregulated as a consequence of ADNP deficiency/mutation including the autophagy and microbiome resilience-linked forkhead box 3 (FOXO3) [112]. This NAP-related transcript regulation may be linked to cell penetration and regulation microtubule dynamics, thereby influencing mRNA levels [109, 113]. The NAP SxIP motif allows further interaction with other SxIP motif-containing proteins, like ADNP [98, 114], and the FOXO3 partner sirtuin 1 (SIRT1) [115] to increase EB1/EB3 and Tau-microtubule binding [22], axonal transport, and dendritic spine formation [114, 116]. Dysregulations of SIRT1 [117], FOXO3 [118], and ADNP [22] are also related to human aging and neurodegeneration. Interestingly, NAP/ADNP regulate tubulin isotype expression levels [98, 112, 119], with increased microtubule microheterogeneity linked to neuronal/brain development [120, 121].

Box 3 Animal models

Full size table

The ADNP, NAP, and Tau interaction

Tau is a microtubule-associated protein important for tubulin assembly and MT stabilization, regulating the localization and function of EB1 and EB3 in neuronal cells [19, 83,81,85]. Tau is broadly expressed in neurons and is associated with different neurodegenerative diseases, called tauopathies, like Alzheimer’s disease [83]. By both binding to EB3, NAP influences Tau-MT association and can protect MTs [85, 123]. The correlation between NAP and Tau is further confirmed by multiple studies that show that NAP can protect against tauopathies. For example, Tau phosphorylation was increased in heterozygous Adnp mice in comparison with Adnp wild-type mice [13]. Similar increases, including increases in Tau deposition (tauopathy), were observed in the Tyr mice, mimicking the most abundant ADNP mutation in children [52]. After intranasal NAP treatment in the mouse models above (and below), as well as in an AD mouse model, a decrease in Tau hyperphosphorylation and a beneficial effect on Aβ aggregation in an early state of the disease (9–12 months) were observed [124, 125]. NAP also increased Tau-MT association in the case of zinc intoxication in cell cultures [123].

Candidate drugs for the Helsmoortel–Van der Aa syndrome

NAP compensates for deficits linked with mutated human ADNP in cell cultures (e.g., MT deficits with truncated ADNP p.Tyr719*, p.Arg730*, and p.Ser404*) [86, 126, 127]. Correspondingly, NAP protects cellular survival and induces neurite outgrowth [119, 128] as well as dendritic spine formation [81, 112, 122], culminating in synaptogenesis [129], which is implicated in neurodevelopmental diseases and autism spectrum disorders (ASDs) [130]. Moreover, NAP, as well as the shorter NAP interacting derivative SxIP motif-containing SKIP (Ser-Lys-Ile-Pro) [98], is beneficial in the haploinsufficient Adnp mouse model, protecting behavior [98, 122], with NAP reducing Tau hyperphosphorylation in the two-month-old haploinsufficient Adnp male mouse brain [13]. This is paralleled by NAP/SKIP protection of MT-ADNP and sex-dependent axonal transport [98, 131], and with decreased testosterone levels paralleling increased tauopathy in humans [132]. In turn, tauopathy correlates with decreased cognition and ADNP levels [88], and increased somatic mutation loads in the aging/human Alzheimer’s disease brain [126].

The haploinsufficient Adnp mouse model (see Box 3) is now complemented by a novel genome edited (CRISPR/Cas9) Tyr-mouse harboring the most prevalent HVDAS mutation (p.Tyr719*, corresponding to mouse p.Tyr718*) [52]. The Tyr-mouse displays phenotypes attributable to heterozygous expression of 50% wild-type Adnp (loss of function) and 50% Tyr-Adnp (potential gain of toxic function) alleles. As indicated above, young (~ 2-month-old) Tyr mice displayed Tau deposition, which was coupled with visual evoked potential (VEP impairments) and amelioration by NAP treatment [52]. Vocalization/communication deficits in Adnp haploinsufficient and Tyr pups [122] were previously correlated with mouse aging/tauopathy [133], connecting aberrant synaptogenesis to synaptic loss and neurodegeneration. The Tyr-mouse findings recapitulate the human tauopathy in a seven-year-old-postmortem ADNP p.His559Glnfs*3 brain [86]. The demonstrated sexual dichotomy of Adnp haploinsufficient mice [23, 98, 105, 122] is further enhanced in the Tyr-mouse. Developmental delays and gait dysfunctions were increased in Tyr females compared to Adnp^± mice, with adult muscle knockdown of Adnp resulting in robust female gait defects, corrected by NAP [134], coupled with sex-muscle-specific differentially expressed genes, also partly corrected by NAP [135]. The mouse models suggest peripheral biomarkers, like FOXO3, and with FOXO3 regulating the microbiome, the ADNP/NAP peripheral biomarkers include a microbiota signature [136]. With extensive preclinical pharmacology, clean safety, pharmacokinetic profile for the intranasal and intravenous administration routes (half-life of 30–120 min) [137,131,139] coupled to clinical efficacy in amnestic mild cognitive impairment and schizophrenia patients [139], and FDA orphan drug and pediatric rare disease designations, the path is cleared for NAP clinical development for the HVDAS.

Other drug candidates developed for the HVDAS include ketamine (ClinicalTrials.gov Identifier: NCT04388774). The ketamine rationale is based on the finding that ketamine increased ADNP expression, however, the possibility of ketamine increasing mutated ADNP expression needs to be further investigated [140,134,142]. Meanwhile, an open label trial of a low doses of ketamine in ten individuals affected with the Helsmoortel–Van der Aa syndrome demonstrated that the drug is well tolerated and considered safe [143]. A nominal improvement in the Clinical Global Impressions—Improvement Scale, was reported, which according to the authors should be interpreted with care due to the study limitations of a small cohort size and the absence of a control group.

ADNP dysregulation in cancer development

Many transcription factors and chromatin regulators that are hit by driver mutations in cancer are also targeted by de novo germline mutations that cause neurodevelopmental syndromes comprising systemic phenotypes along with intellectual disability (ID) and autism spectrum disorder (ASD) [144, 145]. Paradigmatic examples include chromatin regulators such as KMT2D [146], GTF2I [147], EZH2 [148, 149], YY1 [150, 151], and subunits of BAF complex [152, 153]. Similarly to high prevalence of mutations in genes encoding subunits of the SWI/SNF chromatin remodeling complexes or other epigenetic regulators in cancer development, increasing evidence also points to an oncogenic role for ADNP mutations [25, 154,148,156].

In total, 216 ADNP mutations are displayed in the PanCancer database thanks to the OncoVar platform (https://oncovar.org/), which employs published bioinformatics algorithms and incorporated known driver events to identify driver mutations and driver genes (Fig. 4A) [157]. None of those has actually been defined as driver but the gene has been given a driver level score of 2 (i.e., likely pathogenic), and it has been independently identified as a tumor suppressor [142]. The gnomAD database reports mutations that cause loss of function (LoF) and annotate those that do not apparently lead to haploinsufficiency; for instance, mutations are predicted to escape from NMD as ‘not LoF’ [158]. Six frameshift mutations have been curated as not LoF because they end up in the last exon. ADNP has a DNA-binding activity and no catalytic function. Hence, the ablation of its external domains (i.e., likely responsible for protein–protein interaction) caused by these 6 ‘not LoF’ could indeed strongly impact protein function. Cancer-specific missense mutation A1866D in CHD4 C-terminus domain causes a reduction of CHD4 interaction with ADNP, suggesting that ChAHP formation might be perturbed in cancer cells [159]. In fact, CHD4 and several other ADNP interactors are among the top driver genes in the Cancer Genome Atlas (TCGA) (Fig. 4C).

On a structural point of view, cancer-causing ADNP mutations seem distributed all over the protein in the primary structure, but they are close to each other at the tertiary structure (Fig. 4B). NDD-causing mutations affecting protein structure are overrepresented near the ADNP homeobox domain (Fig. 4B), suggesting that both cancer and neurodevelopment entail the disruption of ADNP chromatin-binding activity. Still, we can observe that most ADNP cancer-causing mutations affect the protein primary structure, while several NDD-causing mutations are displaced all over the gene body, suggesting that the former might be more related to the selection of mutations that affect protein activity modulation, while the latter are more generally inactivating. However, it cannot be excluded that the distinct pathogenic outcomes of these mutations, in terms of neurodevelopment or cancer, might rather be a consequence of the time and space of emergence of these mutations during development, like it has been observed for other neurological conditions [160], affecting individuals early—in germinal or multipotent cells during embryogenesis—or late, in somatic cell, during adult life—respectively.

Overall, there is increasing consensus that ADNP contributes to tumorigenesis and cancer progression. Transcriptional assessment of ADNP levels in a large cohort of bladder cancer specimens highlighted a significant overexpression in the patients with tumor progression and the association of higher ADNP protein levels to poor prognosis in such patients [161]. In bladder cancer, ADNP promotes tumor cell growth and proliferation by enhancing the AKT-MDM2-p53 molecular axis which stabilizes cyclin D1 and ultimately leads to cell cycle acceleration from G1 phase to S phase [162]. In another study, ADNP was found to promote bladder cancer cell migration via TGF-β-mediated epithelial-mesenchymal transition (EMT) pathway [161]. In that respect, it is relevant to mention that ADNP was recently identified as a binding partner of the ZEB1/NuRD complex (zinc finger E-box-binding homeobox 1/Nucleosome Remodeling and Deacetylase) which is critically involved in epigenetic cancer programming of EMT hallmarks [163]. ADNP overexpression has also been linked to the pathogenesis of germinal center B cell-type diffuse large B cell lymphoma (GCB-DLBCL); genome-wide screening of cancer-associated super-enhancers in this cell type and other human B cell lymphoma lines revealed the upregulation of ADNP, which is significantly associated with increased risk of death. Moreover, ADNP knockdown in GCB subtypes of B cell lymphoma inhibited proliferation, overall suggesting that epigenetic super-enhancer-mediated control of ADNP contributes to GCB-DLBCL progression [164]. ADNP is also part of a protein hub that is enriched in the signal transduction of pathways involved in colorectal cancer (Rahman et al., 2019). In such context, silencing of ADNP primarily affected Wnt-signaling genes by increasing the expression of many of its effectors such as the tumor drivers DNMT1 and TALIN-1, thus showing an ADNP-mediated repression on the Wnt axis. Moreover, downregulation or depletion of ADNP both in vitro and in tumor xenografts showed increased migration, invasion and proliferation of colon cancer cells resulting in accelerated tumor growth, suggesting a tumor suppressor function of ADNP, and highlighting its potential role as a prognostic biomarker for colorectal cancer. Moreover, pharmacological administration of subnarcotic dosage of ketamine induces ADNP levels thus suppressing tumor growth [142, 165]. Another example of ADNP involvement in aberrant tumorigenic mechanisms is provided by the Malignant Peripheral Nerve Sheath Tumor (MPSNT). This is a highly aggressive comorbid manifestation associated with Neurofibromatosis type 1 and is characterized by abnormal growth under prohibitive metabolic conditions. In the lack of growth-stimulating factors typical of MPSNT niche, the higher endogenous level of PACAP induces the overexpression of ADNP, which in turn provides a protection against H₂O₂-induced oxidative stress, thus mediating an adaptive mechanism that contributes to tumor cell resistance [103]. Finally, genomic and proteomic analyses in High-Grade Serous Ovarian Cancer (HGSOC) cells identified ADNP as a novel altered transcription factor whose gain in DNA copy number and increase in mRNA and protein levels are associated with poor prognosis. ADNP expression is required for cell viability and strongly associated with tumor maturation by impacting on cell cycle progression and proliferation pathway. Indeed, silencing of ADNP markedly reduced cell growth and colony formation, along with a concomitant increase of apoptotic events. To further corroborate this hypothesis, functional enrichment of downregulated genes upon ADNP silencing includes fundamental modulators of cell cycle checkpoints such as CDC25A, a key regulator of both G1/S and G2/M transitions, whose protein levels are reduced upon ADNP silencing [166].

ADNP chromatinopathies disturb higher-order 3D chromatin landscapes

The epigenetic mechanisms by which ADNP chromatinopathies contribute to pleiotropic clinical presentations of ASD, cancer, and neurodegeneration still remain poorly understood [5, 167]. Recent studies have shown that chromatin remodeling complexes play an important role in higher-order chromatin structure in neuronal development and that disruptions during development influence the maturation of neural networks [7, 168,162,163,171]. During cell differentiation, the 3D genome architecture changes dynamically and subsequently alters the regulation of gene expression [172,166,167,168,176]. At the genome level, euchromatic from heterochromatic regions are organized into chromosome territories. These megabase-sized chromatin domains are organized into smaller and smaller subdomains known as topologically associated domains (TADs) [173, 177]. Long-range chromatin contacts that bring genes and regulatory sequences in close proximity in TADs are necessary for co-transcription of biologically related and developmentally co-regulated ASD genes [64, 65, 178,172,173,181]. Recent advances in methodologies based on chromatin conformation capture (3C-Hi-C) start to provide new perspectives on the genome-wide 3D chromatin organization of ADNP chromatinopathies in pathological developmental processes [174].

For example, CTCF-binding sites are known to be spread across the genome by transposable elements (TEs), allowing the formation of complex 3D chromatin architecture via large domains of chromatin, organized into TADs [65, 173, 177]. CTCF in concert with cohesin regulates 3D chromatin loop organization in the genome [65]. Within TADs, long-range chromatin interactions can be created, bringing gene and regulatory sequences together which are required for the co-transcription of ASD genes. These interactions can be disrupted by mutations in chromatin remodelers such as ADNP, an active participant of the ChAHP chromatin remodeling complex. It has been assumed that ADNP, and the entire ChAHP complex, has an important evolutionary role as it prevents rewiring of 3D genome architecture, thereby allowing TE-mediated CTCF motif spreading. ATAC-seq showed that ADNP inhibits cohesin-mediated looping by competing with CTCF at TAD boundaries in Adnp knockout versus wild-type mouse ESCs. Furthermore, 4C-seq experiments have revealed that Adnp knockout causes loss of the Caudal-type homeobox 2 (Cdx2) gene which is involved in trophectoderm specification and maintenance. In wild-type mESCs, the Cdx2 promotor is looped to a locus enriched for histone H3 lysine-27 (H3K27) acetylation, indicating that it is an active enhancer. These H3K27 acetylation levels remain unchanged following Adnp deletion, whereas CTCF and cohesin binding creates a strong loop, weakening the promotor–enhancer interaction, leading to a reduction in Cdx2 expression. In line, Adnp knockout mouse embryos showed impaired formation of the neural tube, which leads to lethality around embryonic day 9.5 [11, 39]. In this respect, it could be argued that different phenotypes in humans with heterozygous ADNP mutations, as seen in HVDAS, could be a consequence of directly affected local perturbations in 3D chromatin organization [65]. Alternatively, ADNP has also been identified as an interaction partner of RNA polymerase III transcription factor C (TFIIIC), which recognizes acetylated Alu elements (AEs) that interact with CTCF-binding sites and show promotor–enhancer functions [182]. This has been investigated by comparing ATAC-seq data from T47D cancer cells growing in normal conditions with T47D cells after 16 h of serum starvation (SS) [182]. Upon SS, TFIIIC is recruited by AEs pre-marked by ADNP, which alters their chromatin accessibility by direct acetylation of H3K18 [182]. Therefore, ADNP together with CTCF could be involved in TFIIIC-mediated long distal looping, supporting the hypothesis that ADNP has a pleiotropic role in 3D chromatin shaping [182]. These interactions may give rise to obvious differences between primates and rodent models, with sequence specificity; however, it is interesting to remember that at the mRNA level ADNP is 90% identical between mouse and humans [14].

Another particular example of higher-order chromatin structure, contributing to genome instability, is the R-loop, defined as a three-stranded nucleic acid structure accumulating on chromatin. These arise as a consequence of transcription, and are comprised of a DNA/RNA hybrid together with a displaced single-stranded DNA (ssDNA) [183,177,178,186]. The displaced ssDNA can fold into a G-quadruplex structure, stabilizing the R-loop and playing a regulatory role during transcription and DNA repair [186]. Temporary regulation by R-loops is important in essential physiological processes such as regulation of gene expression, immunoglobulin class switch recombination, and mitochondrial replication initiation [187, 188]. Importantly, these R-loops should be preserved as they are essential for the regulation of biological relevant processes, while harmful R-loops, associated with several disorders as mentioned above, should rather be eliminated. Elimination of harmful R-loops is facilitated by several factors such as helicases which unwind the DNA/RNA hybrid or G4 structures and ribonuclease H (RNase H) enzymes which directly degrade the RNA within the DNA/RNA hybrids to form double-stranded DNA (dsDNA) [186]. Using a proximity-based labeling approach in vitro, ADNP was found to be highly enriched close to RNase H, proving it directly regulates R-loops. ADNP is involved in R-loop suppression with its associated zinc finger motifs resolving R-loops, while the homeodomain is directing ADNP to chromatin. Several mutations associated with Helsmoortel–Van der Aa syndrome result in loss of the homeodomain, but not of the zinc finger motifs [10, 45]. Without the presence of the DNA-binding homeodomain, ADNP is unable to localize to chromatin associated with R-loop deregulation. It has been found that R-loops accumulate at the ADNP target, which suggests haploinsufficiency is a main underlying cause of HVDAS [186]. However, gain of toxic function is a complementary, confounding phenotype, as described for the currently known, most abundant ADNP p.Tyr719* mutation (p.Tyr718* in mice) truncating the protein at the nuclear localization signal (NLS) and leading to a complex phenotypic outcomes [52].

A concluding look ahead

In this review, we discussed the current knowledge of the chromatin remodeler ADNP, a gene frequently mutated in syndromic autism. Since its discovery, we demonstrate the multimodal aspect of ADNP in various processes by interaction with its protein domains, e.g., regulation of the cytoskeleton by the NAP motif, heterochromatin formation by its PxVxL interaction motif, and DNA binding by the presence of a homeobox domain and zinc fingers. Moreover, we described binding of ADNP to proteins involved in autophagy (LC3), autism pathways (EIF4E/SHANK3), chromatin remodeling (BRG1/HP1/CDH4), and epigenetic modifying genes (SIRT1/HDAC2/YY1), all impacting the physiological status of the cell. Of special note, chromatin remodeling complexes are key regulators of the unfolded protein stress autophagy response to promote clearance of cytoplasmic protein aggregates [189]. Maintenance of protein folding homeostasis, or proteostasis, is crucial for cell survival as well as for execution of cell type-specific biological processes such as neuronal synapse and memory formation, and cell transition from a mitotic to post-mitotic cell type. Besides, several epigenetic chromatin enzymes were recently shown also to remodel the cytoskeleton, regulating structure and function of microtubules and actin filaments [190]. This points to an emerging paradigm for dual-function remodelers with ‘chromatocytoskeletal’ activity that can integrate cytoplasmic and nuclear functions. This epi-chromato-cytoskeletal regulation suggests that cells coordinate epigenetic differentiation programs with acquisition of specialized cytoskeletal structures [191]. Such coordination could affect brain development by coordinating patterns of gene expression with remodeling of the neuronal cytoskeleton. This, in turn, could modify such basic neural functions as learning, memory, and behavior [190, 192].

The nuclear function of ADNP is most often ascribed to chromatin remodeling and shaping the 3D chromatin structure, and the protein has been identified in a multitude of epigenetic complexes. With confirmed interactions in the SWI/SNF and ChAHP complex, ABC-triplex, and POGZ, ADNP was independently associated with binding of HP1, remarkably, in each of the mentioned chromatin remodeling complexes. However, there are contradicting reports whether the α, β, or γ isoform of HP1 is the main interactor. Here, we postulate that which HP1 subunit ADNP binds is dependent of the tested sample material (e.g., cell lines or tissue), species (e.g., mouse or human), and the implemented technique (e.g., CoIP-MS, ChIP-seq). The remarkable interaction with POGZ, of which mutations are causative of the White–Sutton neurodevelopmental disorder, shows striking associations with molecular dysfunctions found in the Helsmoortel–Van der Aa syndrome. Therefore, we stress the necessity for studying the role of the nuclear ADNP-HP1-POGZ complex in the Helsmoortel–Van der Aa syndrome and how mutation of ADNP reflect on the molecular impact of POGZ. Lastly, computational analyses have revealed WRD5-binding sites in ADNP associating it with the epigenetic SIRT1 enzyme. Binding was confirmed by co-immunoprecipitation. Additionally, promotor motif alignments identified similarities of ADNP with YY1, BRG1, and HDAC2. With a confirmed binding to BRG1, chromatin remodelers YY1 and HDAC2 still lack evidence for direct binding to ADNP as well as the impact of HVDAS-related stop mutations on this predicted novel epigenetic complex.

Constitutional stop and frameshift mutations in ADNP cause a form of syndromic autism referred to as the Helsmoortel–Van der Aa syndrome. Most mutations are present in the last exon and escape from NMD. Although mutant mRNA has been detected in patient-derived sample materials and mouse models, we still lack evidence for the presence of a truncated ANDP protein in patient material, though ADNP-mutant protein has been detected in cellular systems when the protein has been engineered to include a Flag® or GFP-tag. The absence of detectable mutant protein could indicate a loss-of-function mechanism. This would be compatible with the relative uniform clinical presentation of individuals with the Helsmoortel–Van der Aa syndrome [45]. However, a presumed uniform mutational mechanism of the disorder is hard to combine with the partially opposing methylation signatures in blood of patients in function of the location of the mutation [57, 58] and potentially with a slightly more severe clinical presentation of patients with a p.Tyr719* mutation [45]. Here, patients with N-terminal mutations as well as with C-terminal mutations showed an overall hypomethylation pattern. However, mutations in the central part of the protein rather presented with a general pattern of hypermethylation. Interestingly, the mutation boundary between hypo- and hypermethylation near the C-terminus is coinciding with the NLS, with mutations before the NLS resulting in hypo and the mutations after the NLS resulting in hypermethylation. This boundary could theoretically be explained by a truncated mutant protein being generated and entering the nucleus if the NLS is present or remaining cytoplasmatic, when the NLS is absent. Overexpression of (mutant) GFP-tagged ADNP in cellular systems confirms that the presence of the intact NLS is responsible for entry in the nucleus. However, such a theoretical model, mutant protein has never been detected in patients, would point to an (additional) gain-of-function/dominant negative function of the ADNP mutations. However, this model cannot explain why N-terminal mutations have an epigenetic effect in patients similar to C-terminal mutations and the mutational mechanism remains to be unveiled.

The ADNP paralogue ADNP2 has not (yet) been linked to any disorder, although some ADNP2 variants were named associated with the onset of schizophrenia [17]. Currently, only one de novo 4.8 Mb heterozygous microdeletion has been identified on chromosome 18q23, taking away the ADNP2 gene among others [193]. The individual with this deletion had a clinical presentation including congenital glaucoma, bilateral microphthalmia, pupil and iris anomalies, dysmorphic facial features, mild cognitive impairment (IQ about 60), congenital deafness. The patient also inherited a pathogenic frameshift mutation in FOXC1 from the father. While the FOXC1 mutation can explain the eye phenotype of the patient, the origin of the other clinical symptoms remains unknown at the moment, but a role for the ADNP2 gene cannot be excluded.

The dual role of ADNP mutations in both neurodevelopment and cancer suggests that altering the core circuitry regulating differentiation has vastly divergent, developmental stage-dependent consequences, with equivalent mutations resulting, in developmental delay or in cancer, depending on whether they are present throughout development or arise after establishment of mature somatic lineages. A thorough meta-analysis of brains from ASD individuals revealed a common ground gene expression dysregulation and biological pathway derailments in cancer [194]. The opposite tendency of developing one condition or another (here ASD and cancer, respectively) within a population is called inverse comorbidity. Extending the case to central nervous systems (CNS) disorders in general [160], large observational studies showed that this is true for several common neurological disorders, and it might be relevant to assess in the case of ADNP. Oncogenic mutations can be exquisitely sensitive to developmental context, as most vividly demonstrated by nuclear transplantation experiments in mice in which egg-mediated reprogramming was able to suppress, through the blastocyst stage, the oncogenic potential of mutant genomes from leukemia, lymphoma, and breast cancer cells [195]. These findings suggest that the regulatory circuitry operating in pluripotent stem cells could counteract the effects of oncogenic mutations, introducing some sort of epigenetic robustness toward cancer that in turn affects neurodevelopment. The possibility to obtain iPSCs from biopsies of cancer patients provides us with a new resource to verify this claim by studying early developmental stage phenotypes of cancer and to characterize cancer progression [196]. These observations acquire significant translational potential with the realization that the identification of these developmental stage-specific pathways for cancer resistance/vulnerability could yield major actionable insights for managing tumors and understanding transcriptional regulation.

Ongoing studies progressively elucidate the underlying gene networks in each system, highlighting the similarities and differences. Remarkably, epithelial-to-mesenchymal transition (EMT) is an essential molecular and cellular process involved in neurodevelopmental morphogenesis (synaptic brain plasticity) as well as cancer stem cell plasticity in malignant cancer metastasis progression [197, 198]. EMT is a central process during brain development that affects selected progenitor cells and drives the onset of cellular migrations and subsequent brain morphogenesis, intimately associated with the segregation of homogeneous precursors (neural crest and somites, progenitors of the peripheral nervous system) into distinct fates. Polarity affects stem cell function and allows stem cells to integrate environmental cues from distinct niches in the developing cerebral cortex or in the tumor microenvironment. The crucial role of polarity in stem and progenitor cells is highlighted by the fact that impairment of cell polarity is linked to both neurodevelopmental disorders such as autism spectrum disorders (ASD) as well as cancer cell metastasis [199]. Future research into the biochemical logic of this normal ontogenetic neurodevelopmental process versus pathological conditions such as metastasis–carcinogenesis will further improve our understanding of the paradoxical pathophysiological roles of ADNP in ASD and cancer metastasis [200, 201].

However, cellular heterogeneity in the human brain and the tumor microenvironment complicates the characterization of functional cellular regulatory circuits to form billions of synaptic neuronal connections or controlling cellular migration, cell proliferation as well as programmed cell death. Given the cellular heterogeneity of brain and cancer samples investigated, spatially mapped chromatin analyses at the single-cell level will be especially informative for future studies of neural disorders and cancer development [202]. The recent implementation of advanced single-cell RNA-seq, ChIP-seq, Cut-Tag-seq, DamID, ATAC-seq, GAM, and Hi-C technologies should prove new insights in this regard [203,197,198,206]. Development of innovative epigenome editing tools will further enable a functional dissection between altered epigenetic chromatin states and disease outcomes [207, 208].

Variations in the chromatin state of the DNA now reveal micro-level regulations, including heterochromatin nanodomains [209, 210]. Heterochromatin nanodomains are short stretches of ~ 3 to 10 nucleosomes worth of DNA (~ 0.7 to 2 kb, where eukaryotic cells have a characteristic average nucleosome spacing of ~ 190 bp, corresponding to a ~ 45 bp linker). Heterochromatin nanodomains can establish cell type- and development-specific chromatin patterns affecting gene expression programs. Strikingly, heterochromatin nanodomains are determined by DNA sequence-specific binding proteins, including the histone methyltransferases SUV39H1 (KMT1A) and SUV39H2 (KMT1B) that set H3K9me3 marks; methyltransferase GLP (G9a like protein, KMT1D) that forms H3K9me; transcription factor ADNP that recruits the chromatin remodeler CHD4 as well as HP1β/γ for H3K9me3 mediated gene silencing; chromatin remodeler ATRX that induces the formation of H3K9me3 heterochromatin nanodomains at repeat sequences. These sequence-binding motifs act as nucleation sites and boundaries, cooperative interactions between nucleosomes as well as nucleosome-HP1 interactions. In fact, the number of ADNP motifs per heterochromatin nanodomain is a very good predictor of the HND size. ADNP, like CTCF, is a zinc finger DNA-binding protein, where the ADNP DNA-binding motifs, like CTCF-binding motifs, encompass a set of unusually long sequences (12-mer for ADNP, ~ 19-mer for CTCF), some of which include methylatable CpG sites [39, 65, 211]. A subset of the ADNP DNA-binding motifs closely resembles a subset of the CTCF DNA-binding motifs. Indeed, ADNP, in the ChAHP complex, can compete against CTCF for binding to a subset of sites. Heterochromatin nanodomains typically involve weak CTCF-binding sites, which are often missed with the typical strong CTCF peak-binding detection thresholds of CTCF ChIP-seq data. It has been suggested that weak CTCF sites may be functionally important in defining nanodomain structures, with transient or competitive binding of CTCF and/or ADNP [209, 210]. The effect of ADNP mutations upon heterochromatin nanodomains is unknown and represents an area of future research.

In summary, we have in this extensive review highlighted two and a half decades of ADNP investigations. It clearly highlights the many suggested functions of the ADNP gene. While a role in chromatin remodeling is obvious, the relative importance of the various interacting complexes is yet to be determined. This is even more true for its suggested cellular functions. Similarly, though mutations in ADNP do result in autism and to play a suggested role in cancer, the mutational mechanism remains to be further investigated. Recent technological developments will now enable us to zoom in on the yet unexplored functions of ADNP and their role in disease.

Availability of data and materials

Not applicable.

Institutional review board statement

Not applicable.

Change history

01 January 2024
The funding section has been corrected.

References

American Psychiatric Association. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. Fifth. Arlington, VA; 2013.
Zhou X, Feliciano P, Shu C, Wang T, Astrovskaya I, Hall JB, et al. Integrating de novo and inherited variants in 42,607 autism cases identifies mutations in new moderate-risk genes. Nat Genet. 2022;54:1305–19. https://doi.org/10.1038/s41588-022-01148-2.
Article CAS PubMed Central PubMed Google Scholar
Fu JM, Satterstrom FK, Peng M, Brand H, Collins RL, Dong S, et al. Rare coding variation provides insight into the genetic architecture and phenotypic context of autism. Nat Genet. 2022;54:1320–31. https://doi.org/10.1038/s41588-022-01104-0.
Article CAS PubMed Central PubMed Google Scholar
Wang T, Kim CN, Bakken TE, Gillentine MA, Henning B, Mao Y, et al. Integrated gene analyses of de novo variants from 46,612 trios with autism and developmental disorders. Proc Natl Acad Sci USA. 2022;119:e2203491119. https://doi.org/10.1073/pnas.2203491119.
Article CAS PubMed Central PubMed Google Scholar
Mossink B, Negwer M, Schubert D, Nadif KN. The emerging role of chromatin remodelers in neurodevelopmental disorders: a developmental perspective. Cell Mol Life Sci. 2021;78:2517–63. https://doi.org/10.1007/s00018-020-03714-5.
Article CAS PubMed Google Scholar
Krumm N, O’Roak BJ, Shendure J, Eichler EE. A de novo convergence of autism genetics and molecular neuroscience. Trends Neurosci. 2014;37:95–105. https://doi.org/10.1016/j.tins.2013.11.005.
Article CAS PubMed Google Scholar
Ciptasari U, van Bokhoven H. The phenomenal epigenome in neurodevelopmental disorders. Hum Mol Genet. 2020;29:R42–50. https://doi.org/10.1093/hmg/ddaa175.
Article CAS PubMed Central PubMed Google Scholar
Gabriele M, Lopez Tobon A, D’Agostino G, Testa G. The chromatin basis of neurodevelopmental disorders: Rethinking dysfunction along the molecular and temporal axes. Prog Neuropsychopharmacol Biol Psychiatry. 2018. https://doi.org/10.1016/j.pnpbp.2017.12.013.
Article PubMed Google Scholar
Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O, et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem. 1999;72:1283–93. https://doi.org/10.1046/j.1471-4159.1999.0721283.x.
Article CAS PubMed Google Scholar
Helsmoortel C, Vulto-van Silfhout AT, Coe BP, Vandeweyer G, Rooms L, van den Ende J, et al. A SWI/SNF-related autism syndrome caused by de novo mutations in ADNP. Nat Genet. 2014;46:380–4. https://doi.org/10.1038/ng.2899.
Article CAS PubMed Central PubMed Google Scholar
Pinhasov A, Mandel S, Torchinsky A, Giladi E, Pittel Z, Goldsweig AM, et al. Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res Dev Brain Res. 2003;144:83–90. https://doi.org/10.1016/s0165-3806(03)00162-7.
Article CAS PubMed Google Scholar
Mandel S, Gozes I. Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex. J Biol Chem. 2007;282:34448–56. https://doi.org/10.1074/jbc.M704756200.
Article CAS PubMed Google Scholar
Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z, et al. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther. 2007;323:438–49. https://doi.org/10.1124/jpet.107.129551.
Article CAS PubMed Google Scholar
Zamostiano R, Pinhasov A, Gelber E, Steingart RA, Seroussi E, Giladi E, et al. Cloning and characterization of the human activity-dependent neuroprotective protein. J Biol Chem. 2001;276:708–14. https://doi.org/10.1074/jbc.M007416200.
Article CAS PubMed Google Scholar
Pascolini G, Agolini E, Majore S, Novelli A, Grammatico P, Digilio MC. Helsmoortel-Van der Aa syndrome as emerging clinical diagnosis in intellectually disabled children with autistic traits and ocular involvement. Eur J Paediatr Neurol. 2018;22:552–7. https://doi.org/10.1016/j.ejpn.2018.01.024.
Article PubMed Google Scholar
D’Amico AG, Maugeri G, Rasà DM, La Cognata V, Saccone S, Federico C, et al. NAP counteracts hyperglycemia/hypoxia induced retinal pigment epithelial barrier breakdown through modulation of HIFs and VEGF expression. J Cell Physiol. 2018;233:1120–8. https://doi.org/10.1002/jcp.25971.
Article CAS PubMed Google Scholar
Dresner E, Agam G, Gozes I. Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia. Eur Neuropsychopharmacol. 2011;21:355–61. https://doi.org/10.1016/j.euroneuro.2010.06.004.
Article CAS PubMed Google Scholar
Magen I, Gozes I. Davunetide: peptide therapeutic in neurological disorders. Curr Med Chem. 2014;21:2591–8. https://doi.org/10.2174/0929867321666140217124945.
Article CAS PubMed Google Scholar
Malishkevich A, Amram N, Hacohen-Kleiman G, Magen I, Giladi E, Gozes I. Activity-dependent neuroprotective protein (ADNP) exhibits striking sexual dichotomy impacting on autistic and Alzheimer’s pathologies. Transl Psychiatry. 2015;5:e501. https://doi.org/10.1038/tp.2014.138.
Article CAS PubMed Central PubMed Google Scholar
Cappuyns E, Huyghebaert J, Vandeweyer G, Kooy RF. Mutations in ADNP affect expression and subcellular localization of the protein. Cell Cycle. 2018;17:1068–75. https://doi.org/10.1080/15384101.2018.1471313.
Article CAS PubMed Central PubMed Google Scholar
Mosch K, Franz H, Soeroes S, Singh PB, Fischle W. HP1 recruits activity-dependent neuroprotective protein to H3K9me3 marked pericentromeric heterochromatin for silencing of major satellite repeats. PLoS ONE. 2011;6:e15894. https://doi.org/10.1371/journal.pone.0015894.
Article CAS PubMed Central PubMed Google Scholar
Hadar A, Kapitansky O, Ganaiem M, Sragovich S, Lobyntseva A, Giladi E, et al. Introducing ADNP and SIRT1 as new partners regulating microtubules and histone methylation. Mol Psychiatry. 2021;26:6550–61. https://doi.org/10.1038/s41380-021-01143-9.
Article CAS PubMed Google Scholar
Merenlender-Wagner A, Malishkevich A, Shemer Z, Udawela M, Gibbons A, Scarr E, et al. Autophagy has a key role in the pathophysiology of schizophrenia. Mol Psychiatry. 2015;20:126–32. https://doi.org/10.1038/mp.2013.174.
Article CAS PubMed Google Scholar
Ivashko-Pachima Y, Ganaiem M, Ben-Horin-Hazak I, Lobyntseva A, Bellaiche N, Fischer I, et al. SH3- and actin-binding domains connect ADNP and SHANK3, revealing a fundamental shared mechanism underlying autism. Mol Psychiatry. 2022;27:3316–27. https://doi.org/10.1038/s41380-022-01603-w.
Article CAS PubMed Google Scholar
Gozes I, Yeheskel A, Pasmanik-Chor M. Activity-dependent neuroprotective protein (ADNP): a case study for highly conserved chordata-specific genes shaping the brain and mutated in cancer. J Alzheimers Dis. 2015;45:57–73. https://doi.org/10.3233/JAD-142490.
Article CAS PubMed Google Scholar
Zhang R, Poustovoitov MV, Ye X, Santos HA, Chen W, Daganzo SM, et al. Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev Cell. 2005;8:19–30. https://doi.org/10.1016/j.devcel.2004.10.019.
Article CAS PubMed Google Scholar
Mandel S, Spivak-Pohis I, Gozes I. ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance. J Mol Neurosci. 2008;35:127–41. https://doi.org/10.1007/s12031-007-9013-y.
Article CAS PubMed Google Scholar
Gozes I, Zamostiano R, Pinhasov A, Bassan M, Giladi E, Steingart RA, et al. A novel VIP responsive gene. Activity dependent neuroprotective protein. Ann N Y Acad Sci. 2000;921:115–8. https://doi.org/10.1111/j.1749-6632.2000.tb06957.x.
Article CAS PubMed Google Scholar
Gennet N, Herden C, Bubb VJ, Quinn JP, Kipar A. Expression of activity-dependent neuroprotective protein in the brain of adult rats. Histol Histopathol. 2008;23:309–17. https://doi.org/10.14670/HH-23.309.
Article CAS PubMed Google Scholar
Furman S, Steingart RA, Mandel S, Hauser JM, Brenneman DE, Gozes I. Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biol. 2004;1:193–9. https://doi.org/10.1017/S1740925X05000013.
Article PubMed Central PubMed Google Scholar
Ganaiem M, Karmon G, Ivashko-Pachima Y, Gozes I. Distinct impairments characterizing different ADNP mutants reveal aberrant cytoplasmic-nuclear crosstalk. Cells. 2022. https://doi.org/10.3390/cells11192994.
Article PubMed Central PubMed Google Scholar
Bennison SA, Blazejewski SM, Liu X, Hacohen-Kleiman G, Sragovich S, Zoidou S, et al. The cytoplasmic localization of ADNP through 14–3-3 promotes sex-dependent neuronal morphogenesis, cortical connectivity, and calcium signaling. Mol Psychiatry. 2023. https://doi.org/10.1038/s41380-022-01939-3.
Article PubMed Google Scholar
Kushnir M, Dresner E, Mandel S, Gozes I. Silencing of the ADNP-family member, ADNP2, results in changes in cellular viability under oxidative stress. J Neurochem. 2008;105:537–45. https://doi.org/10.1111/j.1471-4159.2007.05173.x.
Article CAS PubMed Google Scholar
Dresner E, Malishkevich A, Arviv C, Leibman Barak S, Alon S, Ofir R, et al. Novel evolutionary-conserved role for the activity-dependent neuroprotective protein (ADNP) family that is important for erythropoiesis. J Biol Chem. 2012;287:40173–85. https://doi.org/10.1074/jbc.M112.387027.
Article CAS PubMed Central PubMed Google Scholar
Kosugi S, Hasebe M, Tomita M, Yanagawa H. Systematic identification of cell cycle-dependent yeast nucleocytoplasmic shuttling proteins by prediction of composite motifs. Proc Natl Acad Sci USA. 2009;106:10171–6. https://doi.org/10.1073/pnas.0900604106.
Article PubMed Central PubMed Google Scholar
Sansom SN, Griffiths DS, Faedo A, Kleinjan D-J, Ruan Y, Smith J, et al. The level of the transcription factor Pax6 is essential for controlling the balance between neural stem cell self-renewal and neurogenesis. PLoS Genet. 2009;5:e1000511. https://doi.org/10.1371/journal.pgen.1000511.
Article CAS PubMed Central PubMed Google Scholar
Gressens P, Hill JM, Gozes I, Fridkin M, Brenneman DE. Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature. 1993;362:155–8. https://doi.org/10.1038/362155a0.
Article CAS PubMed Google Scholar
Yoo AS, Crabtree GR. ATP-dependent chromatin remodeling in neural development. Curr Opin Neurobiol. 2009;19:120–6. https://doi.org/10.1016/j.conb.2009.04.006.
Article CAS PubMed Central PubMed Google Scholar
Ostapcuk V, Mohn F, Carl SH, Basters A, Hess D, Iesmantavicius V, et al. Activity-dependent neuroprotective protein recruits HP1 and CHD4 to control lineage-specifying genes. Nature. 2018;557:739–43. https://doi.org/10.1038/s41586-018-0153-8.
Article CAS PubMed Google Scholar
Gozes I, Van Dijck A, Hacohen-Kleiman G, Grigg I, Karmon G, Giladi E, et al. Premature primary tooth eruption in cognitive/motor-delayed ADNP-mutated children. Transl Psychiatry. 2017;7:e1043. https://doi.org/10.1038/tp.2017.27.
Article CAS PubMed Central PubMed Google Scholar
Sun X, Peng X, Cao Y, Zhou Y, Sun Y. ADNP promotes neural differentiation by modulating Wnt/β-catenin signaling. Nat Commun. 2020;11:2984. https://doi.org/10.1038/s41467-020-16799-0.
Article CAS PubMed Central PubMed Google Scholar
Wiese KE, Nusse R, van Amerongen R. Wnt signalling: conquering complexity. Development. 2018. https://doi.org/10.1242/dev.165902.
Article PubMed Google Scholar
Helsmoortel C, Vandeweyer G, Ordoukhanian P, Van Nieuwerburgh F, Van der Aa N, Kooy RF. Challenges and opportunities in the investigation of unexplained intellectual disability using family-based whole-exome sequencing. Clin Genet. 2015;88:140–8. https://doi.org/10.1111/cge.12470.
Article CAS PubMed Google Scholar
Stessman HAF, Xiong B, Coe BP, Wang T, Hoekzema K, Fenckova M, et al. Targeted sequencing identifies 91 neurodevelopmental-disorder risk genes with autism and developmental-disability biases. Nat Genet. 2017;49:515–26. https://doi.org/10.1038/ng.3792.
Article CAS PubMed Central PubMed Google Scholar
Van Dijck A, Vulto-van Silfhout AT, Cappuyns E, van der Werf IM, Mancini GM, Tzschach A, et al. Clinical presentation of a complex neurodevelopmental disorder caused by mutations in ADNP. Biol Psychiatry. 2019;85:287–97. https://doi.org/10.1016/j.biopsych.2018.02.1173.
Article PubMed Google Scholar
Arnett AB, Rhoads CL, Hoekzema K, Turner TN, Gerdts J, Wallace AS, et al. The autism spectrum phenotype in ADNP syndrome. Autism Res. 2018;11:1300–10. https://doi.org/10.1002/aur.1980.
Article PubMed Central PubMed Google Scholar
Levine J, Hakim F, Kooy RF, Gozes I. Vineland adaptive behavior scale in a cohort of four ADNP syndrome patients implicates age-dependent developmental delays with increased impact of activities of daily living. J Mol Neurosci. 2022;72:1531–46. https://doi.org/10.1007/s12031-022-02048-0.
Article CAS PubMed Google Scholar
Siper PM, Layton C, Levy T, Lurie S, Benrey N, Zweifach J, et al. Sensory reactivity symptoms are a core feature of ADNP syndrome irrespective of autism diagnosis. Genes (Basel). 2021. https://doi.org/10.3390/genes12030351.
Article PubMed Central PubMed Google Scholar
Van Dijck A, Vandeweyer G, Kooy F. ADNP-Related Disorder. In: GeneReviews®. Updated 2021 April 15. Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Mirzaa G, et al. editors. Seattle (WA): University of Washington, Seattle; 1993.
Dingemans AJM, Stremmelaar DE, Vissers LELM, Jansen S, Nabais Sá MJ, van Remortele A, et al. Human disease genes website series: An international, open and dynamic library for up-to-date clinical information. Am J Med Genet A. 2021. https://doi.org/10.1002/ajmg.a.62057.
Article PubMed Central PubMed Google Scholar
Vandeweyer G, Helsmoortel C, Van Dijck A, Vulto-van Silfhout AT, Coe BP, Bernier R, et al. The transcriptional regulator ADNP links the BAF (SWI/SNF) complexes with autism. Am J Med Genet C Semin Med Genet. 2014;166C:315–26. https://doi.org/10.1002/ajmg.c.31413.
Article CAS PubMed Google Scholar
Karmon G, Sragovich S, Hacohen-Kleiman G, Ben-Horin-Hazak I, Kasparek P, Schuster B, et al. Novel ADNP syndrome mice reveal dramatic sex-specific peripheral gene expression with brain synaptic and tau pathologies. Biol Psychiatry. 2022;92:81–95. https://doi.org/10.1016/j.biopsych.2021.09.018.
Article CAS PubMed Google Scholar
Mohiuddin M, Kooy RF, Pearson CE. De novo mutations, genetic mosaicism and human disease. Front Genetics. 2022. https://doi.org/10.3389/fgene.2022.983668.
Article Google Scholar
Mohiuddin M, Marusic Z, Anicic M, Anke VD, Cappuyns E, Ludovico R, et al. De Novo, Post-Zygotic, inter-tissue mosaicism of cell autonomous ADNP mutations in autistic individuals: restricted environmental contribution. BioRxiv. 2022. https://doi.org/10.1101/2022.06.21.496616.
Article Google Scholar
D’Gama AM. Somatic mosaicism and autism spectrum disorder. Genes (Basel). 2021. https://doi.org/10.3390/genes12111699.
Article PubMed Central PubMed Google Scholar
Aref-Eshghi E, Kerkhof J, Pedro VP, Groupe DI France, Barat-Houari M, Ruiz-Pallares N, et al. Evaluation of DNA methylation episignatures for diagnosis and phenotype correlations in 42 mendelian neurodevelopmental disorders. Am J Hum Genet. 2020;106:356–70. https://doi.org/10.1016/j.ajhg.2020.01.019.
Article CAS PubMed Central PubMed Google Scholar
Bend EG, Aref-Eshghi E, Everman DB, Rogers RC, Cathey SS, Prijoles EJ, et al. Gene domain-specific DNA methylation episignatures highlight distinct molecular entities of ADNP syndrome. Clin Epigenetics. 2019;11:64. https://doi.org/10.1186/s13148-019-0658-5.
Article CAS PubMed Central PubMed Google Scholar
Breen MS, Garg P, Tang L, Mendonca D, Levy T, Barbosa M, et al. Episignatures stratifying Helsmoortel-van der Aa syndrome show modest correlation with phenotype. Am J Hum Genet. 2020;107:555–63. https://doi.org/10.1016/j.ajhg.2020.07.003.
Article CAS PubMed Central PubMed Google Scholar
Aref-Eshghi E, Bend EG, Colaiacovo S, Caudle M, Chakrabarti R, Napier M, et al. Diagnostic utility of genome-wide DNA methylation testing in genetically unsolved individuals with suspected hereditary conditions. Am J Hum Genet. 2019;104:685–700. https://doi.org/10.1016/j.ajhg.2019.03.008.
Article CAS PubMed Central PubMed Google Scholar
Gozes I, Bassan M, Zamostiano R, Pinhasov A, Davidson A, Giladi E, et al. A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein. Ann N Y Acad Sci. 1999;897:125–35. https://doi.org/10.1111/j.1749-6632.1999.tb07884.x.
Article CAS PubMed Google Scholar
Schirer Y, Malishkevich A, Ophir Y, Lewis J, Giladi E, Gozes I. Novel marker for the onset of frontotemporal dementia: early increase in activity-dependent neuroprotective protein (ADNP) in the face of Tau mutation. PLoS ONE. 2014;9:e87383. https://doi.org/10.1371/journal.pone.0087383.
Article CAS PubMed Central PubMed Google Scholar
Nakamachi T, Ohtaki H, Yofu S, Dohi K, Watanabe J, Hayashi D, et al. Pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 receptor (PAC1R) co-localizes with activity-dependent neuroprotective protein (ADNP) in the mouse brains. Regul Pept. 2008;145:88–95. https://doi.org/10.1016/j.regpep.2007.09.025.
Article CAS PubMed Google Scholar
Mandel S, Rechavi G, Gozes I. Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Dev Biol. 2007;303:814–24. https://doi.org/10.1016/j.ydbio.2006.11.039.
Article CAS PubMed Google Scholar
Sun X, Yu W, Li L, Sun Y. ADNP controls gene expression through local chromatin architecture by association with BRG1 and CHD4. Front Cell Dev Biol. 2020;8:553. https://doi.org/10.3389/fcell.2020.00553.
Article PubMed Central PubMed Google Scholar
Kaaij LJT, Mohn F, van der Weide RH, de Wit E, Bühler M. The ChAHP complex counteracts chromatin looping at CTCF sites that emerged from SINE expansions in mouse. Cell. 2019;178:1437-1451.e14. https://doi.org/10.1016/j.cell.2019.08.007.
Article CAS PubMed Google Scholar
Clapier CR, Iwasa J, Cairns BR, Peterson CL. Mechanisms of action and regulation of ATP-dependent chromatin-remodelling complexes. Nat Rev Mol Cell Biol. 2017;18:407–22. https://doi.org/10.1038/nrm.2017.26.
Article CAS PubMed Central PubMed Google Scholar
Ho L, Crabtree GR. Chromatin remodelling during development. Nature. 2010;463:474–84. https://doi.org/10.1038/nature08911.
Article CAS PubMed Central PubMed Google Scholar
Barisic D, Stadler MB, Iurlaro M, Schübeler D. Mammalian ISWI and SWI/SNF selectively mediate binding of distinct transcription factors. Nature. 2019;569:136–40. https://doi.org/10.1038/s41586-019-1115-5.
Article CAS PubMed Central PubMed Google Scholar
Aydin ÖZ, Vermeulen W, Lans H. ISWI chromatin remodeling complexes in the DNA damage response. Cell Cycle. 2014;13:3016–25. https://doi.org/10.4161/15384101.2014.956551.
Article CAS PubMed Central PubMed Google Scholar
Chen L, Cai Y, Jin J, Florens L, Swanson SK, Washburn MP, et al. Subunit organization of the human INO80 chromatin remodeling complex: an evolutionarily conserved core complex catalyzes ATP-dependent nucleosome remodeling. J Biol Chem. 2011;286:11283–9. https://doi.org/10.1074/jbc.M111.222505.
Article CAS PubMed Central PubMed Google Scholar
Harikumar A, Meshorer E. Chromatin remodeling and bivalent histone modifications in embryonic stem cells. EMBO Rep. 2015;16:1609–19. https://doi.org/10.15252/embr.201541011.
Article CAS PubMed Central PubMed Google Scholar
Vermeulen M, Eberl HC, Matarese F, Marks H, Denissov S, Butter F, et al. Quantitative interaction proteomics and genome-wide profiling of epigenetic histone marks and their readers. Cell. 2010;142:967–80. https://doi.org/10.1016/j.cell.2010.08.020.
Article CAS PubMed Google Scholar
Tolstorukov MY, Sansam CG, Lu P, Koellhoffer EC, Helming KC, Alver BH, et al. Swi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promoters. Proc Natl Acad Sci USA. 2013;110:10165–70. https://doi.org/10.1073/pnas.1302209110.
Article PubMed Central PubMed Google Scholar
Lei I, West J, Yan Z, Gao X, Fang P, Dennis JH, et al. Baf250a protein regulates nucleosome occupancy and histone modifications in priming embryonic stem cell differentiation. J Biol Chem. 2015;290:19343–52. https://doi.org/10.1074/jbc.M115.637389.
Article CAS PubMed Central PubMed Google Scholar
Nozawa R-S, Nagao K, Masuda H-T, Iwasaki O, Hirota T, Nozaki N, et al. Human POGZ modulates dissociation of HP1alpha from mitotic chromosome arms through Aurora B activation. Nat Cell Biol. 2010;12:719–27. https://doi.org/10.1038/ncb2075.
Article CAS PubMed Google Scholar
Markenscoff-Papadimitriou E, Binyameen F, Whalen S, Price J, Lim K, Ypsilanti AR, et al. Autism risk gene POGZ promotes chromatin accessibility and expression of clustered synaptic genes. Cell Rep. 2021;37:110089. https://doi.org/10.1016/j.celrep.2021.110089.
Article CAS PubMed Central PubMed Google Scholar
Divinski I, Mittelman L, Gozes I. A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem. 2004;279:28531–8. https://doi.org/10.1074/jbc.M403197200.
Article CAS PubMed Google Scholar
Gozes I. ADNP regulates cognition: A multitasking protein. Front Neurosci. 2018;12:873. https://doi.org/10.3389/fnins.2018.00873.
Article PubMed Central PubMed Google Scholar
Logan CM, Menko AS. Microtubules: Evolving roles and critical cellular interactions. Exp Biol Med. 2019;244:1240–54. https://doi.org/10.1177/1535370219867296.
Article CAS Google Scholar
Holtser-Cochav M, Divinski I, Gozes I. Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL. J Mol Neurosci. 2006;28:303–7. https://doi.org/10.1385/JMN:28:3:303.
Article CAS PubMed Google Scholar
Oz S, Kapitansky O, Ivashco-Pachima Y, Malishkevich A, Giladi E, Skalka N, et al. The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins. Mol Psychiatry. 2014;19:1115–24. https://doi.org/10.1038/mp.2014.97.
Article CAS PubMed Google Scholar
Malishkevich A, Leyk J, Goldbaum O, Richter-Landsberg C, Gozes I. ADNP/ADNP2 expression in oligodendrocytes: implication for myelin-related neurodevelopment. J Mol Neurosci. 2015;57:304–13. https://doi.org/10.1007/s12031-015-0640-4.
Article CAS PubMed Google Scholar
Chong FP, Ng KY, Koh RY, Chye SM. Tau proteins and tauopathies in alzheimer’s disease. Cell Mol Neurobiol. 2018;38:965–80. https://doi.org/10.1007/s10571-017-0574-1.
Article CAS PubMed Google Scholar
Trojanowski JQ, Schuck T, Schmidt ML, Lee VM. Distribution of tau proteins in the normal human central and peripheral nervous system. J Histochem Cytochem. 1989;37:209–15. https://doi.org/10.1177/37.2.2492045.
Article CAS PubMed Google Scholar
Ivashko-Pachima Y, Hadar A, Grigg I, Korenková V, Kapitansky O, Karmon G, et al. Discovery of autism/intellectual disability somatic mutations in Alzheimer’s brains: mutated ADNP cytoskeletal impairments and repair as a case study. Mol Psychiatry. 2021;26:1619–33. https://doi.org/10.1038/s41380-019-0563-5.
Article CAS PubMed Google Scholar
Grigg I, Ivashko-Pachima Y, Hait TA, Korenková V, Touloumi O, Lagoudaki R, et al. Tauopathy in the young autistic brain: novel biomarker and therapeutic target. Transl Psychiatry. 2020;10:228. https://doi.org/10.1038/s41398-020-00904-4.
Article CAS PubMed Central PubMed Google Scholar
Fernandez-Montesinos R, Torres M, Baglietto-Vargas D, Gutierrez A, Gozes I, Vitorica J, et al. Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer’s disease. J Mol Neurosci. 2010;41:114–20. https://doi.org/10.1007/s12031-009-9300-x.
Article CAS PubMed Google Scholar
Malishkevich A, Marshall GA, Schultz AP, Sperling RA, Aharon-Peretz J, Gozes I. Blood-borne activity-dependent neuroprotective protein (ADNP) is correlated with premorbid intelligence, clinical stage, and Alzheimer’s disease biomarkers. J Alzheimers Dis. 2016;50:249–60. https://doi.org/10.3233/JAD-150799.
Article CAS PubMed Google Scholar
Yang M-H, Yang Y-H, Lu C-Y, Jong S-B, Chen L-J, Lin Y-F, et al. Activity-dependent neuroprotector homeobox protein: A candidate protein identified in serum as diagnostic biomarker for Alzheimer’s disease. J Proteomics. 2012;75:3617–29. https://doi.org/10.1016/j.jprot.2012.04.017.
Article CAS PubMed Google Scholar
He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet. 2009;43:67–93. https://doi.org/10.1146/annurev-genet-102808-114910.
Article CAS PubMed Central PubMed Google Scholar
Lin Y-H, Huang Y-C, Chen L-H, Chu P-M. Autophagy in cancer stem/progenitor cells. Cancer Chemother Pharmacol. 2015;75:879–86. https://doi.org/10.1007/s00280-014-2634-2.
Article PubMed Google Scholar
Guo JY, White E. Autophagy, metabolism, and cancer. Cold Spring Harb Symp Quant Biol. 2016;81:73–8. https://doi.org/10.1101/sqb.2016.81.030981.
Article PubMed Google Scholar
Rocchi A, He C. Emerging roles of autophagy in metabolism and metabolic disorders. Front Biol (Beijing). 2015;10:154–64. https://doi.org/10.1007/s11515-015-1354-2.
Article CAS PubMed Google Scholar
Liu J, Li L. Targeting autophagy for the treatment of alzheimer’s disease: challenges and opportunities. Front Mol Neurosci. 2019;12:203. https://doi.org/10.3389/fnmol.2019.00203.
Article CAS PubMed Central PubMed Google Scholar
Lieberman OJ, Cartocci V, Pigulevskiy I, Molinari M, Carbonell J, Broseta MB, et al. mTOR suppresses macroautophagy during striatal postnatal development and is hyperactive in mouse models of autism spectrum disorders. Front Cell Neurosci. 2020;14:70. https://doi.org/10.3389/fncel.2020.00070.
Article CAS PubMed Central PubMed Google Scholar
Schmitz KJ, Ademi C, Bertram S, Schmid KW, Baba HA. Prognostic relevance of autophagy-related markers LC3, p62/sequestosome 1, Beclin-1 and ULK1 in colorectal cancer patients with respect to KRAS mutational status. World J Surg Oncol. 2016;14:189. https://doi.org/10.1186/s12957-016-0946-x.
Article PubMed Central PubMed Google Scholar
Meng T, Lin S, Zhuang H, Huang H, He Z, Hu Y, et al. Recent progress in the role of autophagy in neurological diseases. Cell Stress. 2019;3:141–61. https://doi.org/10.15698/cst2019.05.186.
Article CAS PubMed Central PubMed Google Scholar
Amram N, Hacohen-Kleiman G, Sragovich S, Malishkevich A, Katz J, Touloumi O, et al. Sexual divergence in microtubule function: the novel intranasal microtubule targeting SKIP normalizes axonal transport and enhances memory. Mol Psychiatry. 2016;21:1467–76. https://doi.org/10.1038/mp.2015.208.
Article CAS PubMed Google Scholar
Gozes I. Sexual divergence in activity-dependent neuroprotective protein impacting autism, schizophrenia, and Alzheimer’s disease. J Neurosci Res. 2017;95:652–60. https://doi.org/10.1002/jnr.23808.
Article CAS PubMed Google Scholar
Sragovich S, Merenlender-Wagner A, Gozes I. ADNP plays a key role in autophagy: from autism to schizophrenia and Alzheimer’s disease. BioEssays. 2017. https://doi.org/10.1002/bies.201700054.
Article PubMed Google Scholar
Wang X, Michaelis EK. Selective neuronal vulnerability to oxidative stress in the brain. Front Aging Neurosci. 2010;2:12. https://doi.org/10.3389/fnagi.2010.00012.
Article PubMed Central PubMed Google Scholar
Steingart RA, Gozes I. Recombinant activity-dependent neuroprotective protein protects cells against oxidative stress. Mol Cell Endocrinol. 2006;252:148–53. https://doi.org/10.1016/j.mce.2006.03.029.
Article CAS PubMed Google Scholar
Castorina A, Giunta S, Scuderi S, D’Agata V. Involvement of PACAP/ADNP signaling in the resistance to cell death in malignant peripheral nerve sheath tumor (MPNST) cells. J Mol Neurosci. 2012;48:674–83. https://doi.org/10.1007/s12031-012-9755-z.
Article CAS PubMed Google Scholar
Gozes I. VIP–PACAP 2010: my own perspective on modulation of cognitive and emotional behavior. J Mol Neurosci. 2010;42:261–3. https://doi.org/10.1007/s12031-010-9456-4.
Article CAS PubMed Google Scholar
Sragovich S, Ziv Y, Vaisvaser S, Shomron N, Hendler T, Gozes I. The autism-mutated ADNP plays a key role in stress response. Transl Psychiatry. 2019;9:235. https://doi.org/10.1038/s41398-019-0569-4.
Article CAS PubMed Central PubMed Google Scholar
Brenneman DE, Gozes I. A femtomolar-acting neuroprotective peptide. J Clin Invest. 1996;97:2299–307. https://doi.org/10.1172/JCI118672.
Article CAS PubMed Central PubMed Google Scholar
Gozes I, Sragovich S, Schirer Y, Idan-Feldman A. D-SAL and NAP: two peptides sharing a SIP domain. J Mol Neurosci. 2016;59:220–31. https://doi.org/10.1007/s12031-015-0701-8.
Article CAS PubMed Google Scholar
Yenjerla M, LaPointe NE, Lopus M, Cox C, Jordan MA, Feinstein SC, et al. The neuroprotective peptide NAP does not directly affect polymerization or dynamics of reconstituted neural microtubules. J Alzheimers Dis. 2010;19:1377–86. https://doi.org/10.3233/JAD-2010-1335.
Article CAS PubMed Central PubMed Google Scholar
Ivashko-Pachima Y, Gozes I. Deciphering the enigma: NAP (CP201) the active ADNP drug candidate enters cells by dynamin-associated endocytosis. J Mol Neurosci. 2020;70:993–8. https://doi.org/10.1007/s12031-020-01632-6.
Article CAS PubMed Google Scholar
Merenlender-Wagner A, Shemer Z, Touloumi O, Lagoudaki R, Giladi E, Andrieux A, et al. New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia. Autophagy. 2014;10:2324–32. https://doi.org/10.4161/15548627.2014.984274.
Article CAS PubMed Google Scholar
Esteves AR, Gozes I, Cardoso SM. The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson’s disease. Biochim Biophys Acta. 2014;1842:7–21. https://doi.org/10.1016/j.bbadis.2013.10.003.
Article CAS PubMed Google Scholar
Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 2017;171:1437-1452.e17. https://doi.org/10.1016/j.cell.2017.10.049.
Article CAS PubMed Central PubMed Google Scholar
Venit T, Dowaidar M, Gestin M, Mahmood SR, Langel Ü, Percipalle P. Transcriptional profiling reveals ribosome biogenesis, microtubule dynamics and expression of specific lncRNAs to be part of a common response to cell-penetrating peptides. Biomolecules. 2020. https://doi.org/10.3390/biom10111567.
Article PubMed Central PubMed Google Scholar
De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE, et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature. 2014;515:209–15. https://doi.org/10.1038/nature13772.
Article CAS PubMed Central PubMed Google Scholar
Zhou F, Wang Y-K, Zhang C-G, Wu B-Y. miR-19a/b-3p promotes inflammation during cerebral ischemia/reperfusion injury via SIRT1/FoxO3/SPHK1 pathway. J Neuroinflammation. 2021;18:122. https://doi.org/10.1186/s12974-021-02172-5.
Article CAS PubMed Central PubMed Google Scholar
Ivashko-Pachima Y, Gozes I. Activity-dependent neuroprotective protein (ADNP)-end-binding protein (EB) interactions regulate microtubule dynamics toward protection against tauopathy. Prog Mol Biol Transl Sci. 2021;177:65–90. https://doi.org/10.1016/bs.pmbts.2020.07.008.
Article CAS PubMed Google Scholar
Hadar A, Milanesi E, Walczak M, Puzianowska-Kuźnicka M, Kuźnicki J, Squassina A, et al. SIRT1, miR-132 and miR-212 link human longevity to Alzheimer’s disease. Sci Rep. 2018;8:8465. https://doi.org/10.1038/s41598-018-26547-6.
Article CAS PubMed Central PubMed Google Scholar
Bae H, Gurinovich A, Malovini A, Atzmon G, Andersen SL, Villa F, et al. Effects of FOXO3 polymorphisms on survival to extreme longevity in four centenarian studies. J Gerontol A, Biol Sci Med Sci. 2018;73:1439–47. https://doi.org/10.1093/gerona/glx124.
Article CAS PubMed Google Scholar
Oz S, Ivashko-Pachima Y, Gozes I. The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities. PLoS ONE. 2012;7:e51458. https://doi.org/10.1371/journal.pone.0051458.
Article CAS PubMed Central PubMed Google Scholar
Gozes I, Sweadner KJ. Multiple tubulin forms are expressed by a single neurone. Nature. 1981;294:477–80. https://doi.org/10.1038/294477a0.
Article CAS PubMed Google Scholar
Gozes I, Littauer UZ. Tubulin microheterogeneity increases with rat brain maturation. Nature. 1978;276:411–3. https://doi.org/10.1038/276411a0.
Article CAS PubMed Google Scholar
Hacohen-Kleiman G, Sragovich S, Karmon G, Gao AYL, Grigg I, Pasmanik-Chor M, et al. Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome. J Clin Invest. 2018;128:4956–69. https://doi.org/10.1172/JCI98199.
Article PubMed Central PubMed Google Scholar
Ivashko-Pachima Y, Sayas CL, Malishkevich A, Gozes I. ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy. Mol Psychiatry. 2017;22:1335–44. https://doi.org/10.1038/mp.2016.255.
Article CAS PubMed Google Scholar
Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, Mattson MP, et al. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer’s disease at early pathological stage. J Mol Neurosci. 2007;31:165–170. https://doi.org/10.1385/jmn/31:02:165.
Article CAS PubMed Google Scholar
Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li H-F, et al. A neuronal microtubuleinteracting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer’s disease. J Pharmacol Exp Ther. 2008;325:146–153. doi:10.1124/jpet.107.130526
Article CAS PubMed Google Scholar
Gozes I, Ivashko-Pachima Y, Kapitansky O, Sayas CL, Iram T. Single-cell analysis of cytoskeleton dynamics: From isoelectric focusing to live cell imaging and RNA-seq. J Neurosci Methods. 2019;323:119–24. https://doi.org/10.1016/j.jneumeth.2019.05.014.
Article CAS PubMed Google Scholar
Mollinedo P, Kapitansky O, Gonzalez-Lamuño D, Zaslavsky A, Real P, Gozes I, et al. Cellular and animal models of skin alterations in the autism-related ADNP syndrome. Sci Rep. 2019;9:736. https://doi.org/10.1038/s41598-018-36859-2.
Article CAS PubMed Central PubMed Google Scholar
Smith-Swintosky VL, Gozes I, Brenneman DE, D’Andrea MR, Plata-Salaman CR. Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures. J Mol Neurosci. 2005;25:225–38. https://doi.org/10.1385/JMN:25:3:225.
Article CAS PubMed Google Scholar
Pascual M, Guerri C. The peptide NAP promotes neuronal growth and differentiation through extracellular signal-regulated protein kinase and Akt pathways, and protects neurons co-cultured with astrocytes damaged by ethanol. J Neurochem. 2007;103:557–68. https://doi.org/10.1111/j.1471-4159.2007.04761.x.
Article CAS PubMed Google Scholar
Patel S, Roncaglia P, Lovering RC. Using Gene Ontology to describe the role of the neurexin-neuroligin-SHANK complex in human, mouse and rat and its relevance to autism. BMC Bioinform. 2015;16:186. https://doi.org/10.1186/s12859-015-0622-0.
Article Google Scholar
Jouroukhin Y, Ostritsky R, Assaf Y, Pelled G, Giladi E, Gozes I. NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport. Neurobiol Dis. 2013;56:79–94. https://doi.org/10.1016/j.nbd.2013.04.012.
Article CAS PubMed Google Scholar
Sundermann EE, Panizzon MS, Chen X, Andrews M, Galasko D, Banks SJ, et al. Sex differences in Alzheimer’s-related Tau biomarkers and a mediating effect of testosterone. Biol Sex Differ. 2020;11:33. https://doi.org/10.1186/s13293-020-00310-x.
Article CAS PubMed Central PubMed Google Scholar
Menuet C, Cazals Y, Gestreau C, Borghgraef P, Gielis L, Dutschmann M, et al. Age-related impairment of ultrasonic vocalization in Tau.P301L mice: possible implication for progressive language disorders. PLoS ONE. 2011;6:e25770. https://doi.org/10.1371/journal.pone.0025770.
Article CAS PubMed Central PubMed Google Scholar
Kapitansky O, Karmon G, Sragovich S, Hadar A, Shahoha M, Jaljuli I, et al. Single cell ADNP predictive of human muscle disorders: mouse knockdown results in muscle wasting. Cells. 2020. https://doi.org/10.3390/cells9102320.
Article PubMed Central PubMed Google Scholar
Kapitansky O, Sragovich S, Jaljuli I, Hadar A, Giladi E, Gozes I. Age and sex-dependent ADNP regulation of muscle gene expression is correlated with motor behavior: possible feedback mechanism with PACAP. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21186715.
Article PubMed Central PubMed Google Scholar
Kapitansky O, Giladi E, Jaljuli I, Bereswill S, Heimesaat MM, Gozes I. Microbiota changes associated with ADNP deficiencies: rapid indicators for NAP (CP201) treatment of the ADNP syndrome and beyond. J Neural Transm. 2020;127:251–63. https://doi.org/10.1007/s00702-020-02155-5.
Article CAS PubMed Google Scholar
Spong CY, Abebe DT, Gozes I, Brenneman DE, Hill JM. Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome. J Pharmacol Exp Ther. 2001;297:774–9.
CAS PubMed Google Scholar
Morimoto BH, Fox AW, Stewart AJ, Gold M. Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases. Expert Rev Clin Pharmacol. 2013;6:483–502. https://doi.org/10.1586/17512433.2013.827403.
Article CAS PubMed Google Scholar
Gozes I. The ADNP syndrome and CP201 (NAP) potential and hope. Front Neurol. 2020;11:608444. https://doi.org/10.3389/fneur.2020.608444.
Article PubMed Central PubMed Google Scholar
Brown BP, Kang SC, Gawelek K, Zacharias RA, Anderson SR, Turner CP, et al. In vivo and in vitro ketamine exposure exhibits a dose-dependent induction of activity-dependent neuroprotective protein in rat neurons. Neuroscience. 2015;290:31–40. https://doi.org/10.1016/j.neuroscience.2014.12.076.
Article CAS PubMed Google Scholar
Turner CP, Gutierrez S, Liu C, Miller L, Chou J, Finucane B, et al. Strategies to defeat ketamine-induced neonatal brain injury. Neuroscience. 2012;210:384–92. https://doi.org/10.1016/j.neuroscience.2012.02.015.
Article CAS PubMed Google Scholar
Blaj C, Bringmann A, Schmidt EM, Urbischek M, Lamprecht S, Fröhlich T, et al. ADNP is a therapeutically inducible repressor of WNT signaling in colorectal cancer. Clin Cancer Res. 2017;23:2769–80. https://doi.org/10.1158/1078-0432.CCR-16-1604.
Article CAS PubMed Google Scholar
Kolevzon A, Levy T, Barkley S, Bedrosian-Sermone S, Davis M, Foss-Feig J, et al. An open-label study evaluating the safety, behavioral, and electrophysiological outcomes of low-dose ketamine in children with ADNP syndrome. HGG Adv. 2022;3:100138. https://doi.org/10.1016/j.xhgg.2022.100138.
Article CAS PubMed Central PubMed Google Scholar
Crawley JN, Heyer W-D, LaSalle JM. Autism and cancer share risk genes, pathways, and drug targets. Trends Genet. 2016;32:139–46. https://doi.org/10.1016/j.tig.2016.01.001.
Article CAS PubMed Central PubMed Google Scholar
Vitriolo A, Gabriele M, Testa G. From enhanceropathies to the epigenetic manifold underlying human cognition. Hum Mol Genet. 2019;28:R226–34. https://doi.org/10.1093/hmg/ddz196.
Article CAS PubMed Central PubMed Google Scholar
Guo C, Chen LH, Huang Y, Chang C-C, Wang P, Pirozzi CJ, et al. KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation. Oncotarget. 2013;4:2144–53. https://doi.org/10.18632/oncotarget.1555.
Article PubMed Central PubMed Google Scholar
Petrini I, Meltzer PS, Kim I-K, Lucchi M, Park K-S, Fontanini G, et al. A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nat Genet. 2014;46:844–9. https://doi.org/10.1038/ng.3016.
Article CAS PubMed Central PubMed Google Scholar
Italiano A. Role of the EZH2 histone methyltransferase as a therapeutic target in cancer. Pharmacol Ther. 2016;165:26–31. https://doi.org/10.1016/j.pharmthera.2016.05.003.
Article CAS PubMed Google Scholar
Gall Trošelj K, Novak Kujundzic R, Ugarkovic D. Polycomb repressive complex’s evolutionary conserved function: the role of EZH2 status and cellular background. Clin Epigenetics. 2016;8:55. https://doi.org/10.1186/s13148-016-0226-1.
Article CAS PubMed Central PubMed Google Scholar
Kaufhold S, Garbán H, Bonavida B. Yin Yang 1 is associated with cancer stem cell transcription factors (SOX2, OCT4, BMI1) and clinical implication. J Exp Clin Cancer Res. 2016;35:84. https://doi.org/10.1186/s13046-016-0359-2.
Article CAS PubMed Central PubMed Google Scholar
Shi J, Hao A, Zhang Q, Sui G. The role of YY1 in oncogenesis and its potential as a drug target in cancer therapies. Curr Cancer Drug Targets. 2015;15:145–57. https://doi.org/10.2174/1568009615666150131124200.
Article CAS PubMed Google Scholar
Kadoch C, Crabtree GR. Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. Sci Adv. 2015;1:e1500447. https://doi.org/10.1126/sciadv.1500447.
Article CAS PubMed Central PubMed Google Scholar
Son EY, Crabtree GR. The role of BAF (mSWI/SNF) complexes in mammalian neural development. Am J Med Genet C Semin Med Genet. 2014;166C:333–49. https://doi.org/10.1002/ajmg.c.31416.
Article CAS PubMed Google Scholar
Lu C, Allis CD. SWI/SNF complex in cancer. Nat Genet. 2017;49:178–9. https://doi.org/10.1038/ng.3779.
Article CAS PubMed Central PubMed Google Scholar
Centore RC, Sandoval GJ, Soares LMM, Kadoch C, Chan HM. Mammalian SWI/SNF chromatin remodeling complexes: emerging mechanisms and therapeutic strategies. Trends Genet. 2020;36:936–50. https://doi.org/10.1016/j.tig.2020.07.011.
Article CAS PubMed Google Scholar
Wanior M, Krämer A, Knapp S, Joerger AC. Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapy. Oncogene. 2021;40:3637–54. https://doi.org/10.1038/s41388-021-01781-x.
Article CAS PubMed Central PubMed Google Scholar
Wang T, Ruan S, Zhao X, Shi X, Teng H, Zhong J, et al. OncoVar: an integrated database and analysis platform for oncogenic driver variants in cancers. Nucleic Acids Res. 2021;49:D1289–301. https://doi.org/10.1093/nar/gkaa1033.
Article CAS PubMed Google Scholar
Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434–43. https://doi.org/10.1038/s41586-020-2308-7.
Article CAS PubMed Central PubMed Google Scholar
Sharifi Tabar M, Giardina C, Feng Y, Francis H, Moghaddas Sani H, Low JKK, et al. Unique protein interaction networks define the chromatin remodelling module of the NuRD complex. FEBS J. 2022;289:199–214. https://doi.org/10.1111/febs.16112.
Article CAS PubMed Google Scholar
Catalá-López F, Suárez-Pinilla M, Suárez-Pinilla P, Valderas JM, Gómez-Beneyto M, Martinez S, et al. Inverse and direct cancer comorbidity in people with central nervous system disorders: a meta-analysis of cancer incidence in 577,013 participants of 50 observational studies. Psychother Psychosom. 2014;83:89–105. https://doi.org/10.1159/000356498.
Article PubMed Google Scholar
Xie Y, Zhu S, Zang J, Wu G, Wen Y, Liang Y, et al. ADNP prompts the cisplatin-resistance of bladder cancer via TGF-β-mediated epithelial-mesenchymal transition (EMT) pathway. J Cancer. 2021;12:5114–24. https://doi.org/10.7150/jca.58049.
Article CAS PubMed Central PubMed Google Scholar
Zhu S, Xu Z, Zeng Y, Long Y, Fan G, Ding Q, et al. ADNP upregulation promotes bladder cancer cell proliferation via the AKT pathway. Front Oncol. 2020;10:491129. https://doi.org/10.3389/fonc.2020.491129.
Article PubMed Central PubMed Google Scholar
Manshouri R, Coyaud E, Kundu ST, Peng DH, Stratton SA, Alton K, et al. ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancer. Nat Commun. 2019;10:5125. https://doi.org/10.1038/s41467-019-12832-z.
Article CAS PubMed Central PubMed Google Scholar
Li X, Duan Y, Hao Y. Identification of super enhancer-associated key genes for prognosis of germinal center B-cell type diffuse large B-cell lymphoma by integrated analysis. BMC Med Genomics. 2021;14:69. https://doi.org/10.1186/s12920-021-00916-z.
Article CAS PubMed Central PubMed Google Scholar
Rahman MR, Islam T, Gov E, Turanli B, Gulfidan G, Shahjaman M, et al. Identification of prognostic biomarker signatures and candidate drugs in colorectal cancer: insights from systems biology analysis. Medicina (Kaunas). 2019. https://doi.org/10.3390/medicina55010020.
Article PubMed Google Scholar
Karagoz K, Mehta GA, Khella CA, Khanna P, Gatza ML. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis. EBioMedicine. 2019;50:191–202. https://doi.org/10.1016/j.ebiom.2019.11.009.
Article CAS PubMed Central PubMed Google Scholar
Reichard J, Zimmer-Bensch G. The epigenome in neurodevelopmental disorders. Front Neurosci. 2021;15:776809. https://doi.org/10.3389/fnins.2021.776809.
Article PubMed Central PubMed Google Scholar
Coda DM, Gräff J. Neurogenetic and neuroepigenetic mechanisms in cognitive health and disease. Front Mol Neurosci. 2020;13:205. https://doi.org/10.3389/fnmol.2020.589109.
Article CAS PubMed Central PubMed Google Scholar
Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, et al. Identification of common genetic risk variants for autism spectrum disorder. Nat Genet. 2019;51:431–44. https://doi.org/10.1038/s41588-019-0344-8.
Article CAS PubMed Central PubMed Google Scholar
Kishi Y, Gotoh Y. Regulation of chromatin structure during neural development. Front Neurosci. 2018;12:874. https://doi.org/10.3389/fnins.2018.00874.
Article PubMed Central PubMed Google Scholar
Magaña-Acosta M, Valadez-Graham V. Chromatin remodelers in the 3D nuclear compartment. Front Genet. 2020;11:600615. https://doi.org/10.3389/fgene.2020.600615.
Article CAS PubMed Central PubMed Google Scholar
Bonev B, Mendelson Cohen N, Szabo Q, Fritsch L, Papadopoulos GL, Lubling Y, et al. Multiscale 3D genome rewiring during mouse neural development. Cell. 2017;171:557-572.e24. https://doi.org/10.1016/j.cell.2017.09.043.
Article CAS PubMed Central PubMed Google Scholar
Dekker J, Belmont AS, Guttman M, Leshyk VO, Lis JT, Lomvardas S, et al. The 4D nucleome project. Nature. 2017;549:219–26. https://doi.org/10.1038/nature23884.
Article CAS PubMed Central PubMed Google Scholar
Hu B, Won H, Mah W, Park RB, Kassim B, Spiess K, et al. Neuronal and glial 3D chromatin architecture informs the cellular etiology of brain disorders. Nat Commun. 2021;12:3968. https://doi.org/10.1038/s41467-021-24243-0.
Article CAS PubMed Central PubMed Google Scholar
Spielmann M, Lupiáñez DG, Mundlos S. Structural variation in the 3D genome. Nat Rev Genet. 2018;19:453–67. https://doi.org/10.1038/s41576-018-0007-0.
Article CAS PubMed Google Scholar
Babaei S, Mahfouz A, Hulsman M, Lelieveldt BPF, de Ridder J, Reinders M. Hi-C chromatin interaction networks predict co-expression in the mouse cortex. PLoS Comput Biol. 2015;11:e1004221. https://doi.org/10.1371/journal.pcbi.1004221.
Article CAS PubMed Central PubMed Google Scholar
Tena JJ, Santos-Pereira JM. Topologically associating domains and regulatory landscapes in development, evolution and disease. Front Cell Dev Biol. 2021;9:702787. https://doi.org/10.3389/fcell.2021.702787.
Article PubMed Central PubMed Google Scholar
Linares-Saldana R, Kim W, Bolar NA, Zhang H, Koch-Bojalad BA, Yoon S, et al. BRD4 orchestrates genome folding to promote neural crest differentiation. Nat Genet. 2021;53:1480–92. https://doi.org/10.1038/s41588-021-00934-8.
Article CAS PubMed Central PubMed Google Scholar
Poeta L, Padula A, Lioi MB, van Bokhoven H, Miano MG. Analysis of a set of KDM5C regulatory genes mutated in neurodevelopmental disorders identifies temporal coexpression brain signatures. Genes (Basel). 2021. https://doi.org/10.3390/genes12071088.
Article PubMed Central PubMed Google Scholar
Golovina E, Fadason T, Lints TJ, Walker C, Vickers MH, O’Sullivan JM. Understanding the impact of SNPs associated with autism spectrum disorder on biological pathways in the human fetal and adult cortex. Sci Rep. 2021;11:15867. https://doi.org/10.1038/s41598-021-95447-z.
Article CAS PubMed Central PubMed Google Scholar
Sun Y, Yao X, March ME, Meng X, Li J, Wei Z, et al. Target genes of autism risk loci in brain frontal cortex. Front Genet. 2019;10:707. https://doi.org/10.3389/fgene.2019.00707.
Article CAS PubMed Central PubMed Google Scholar
Ferrari R, Llobet Cucalon LI, Di Vona C, Vidal E, Lioutas A, Le Dilly F, et al. TFIIIC dynamically binds Alu elements to control gene expression through chromatin looping. BioRxiv. 2018. https://doi.org/10.1101/455733.
Article Google Scholar
Thomas M, White RL, Davis RW. Hybridization of RNA to double-stranded DNA: formation of R-loops. Proc Natl Acad Sci USA. 1976;73:2294–8. https://doi.org/10.1073/pnas.73.7.2294.
Article CAS PubMed Central PubMed Google Scholar
Sanz LA, Hartono SR, Lim YW, Steyaert S, Rajpurkar A, Ginno PA, et al. Prevalent, dynamic, and conserved r-loop structures associate with specific epigenomic signatures in mammals. Mol Cell. 2016;63:167–78. https://doi.org/10.1016/j.molcel.2016.05.032.
Article CAS PubMed Central PubMed Google Scholar
Ginno PA, Lott PL, Christensen HC, Korf I, Chédin F. R-loop formation is a distinctive characteristic of unmethylated human CpG island promoters. Mol Cell. 2012;45:814–25. https://doi.org/10.1016/j.molcel.2012.01.017.
Article CAS PubMed Central PubMed Google Scholar
Yan Q, Wulfridge P, Doherty J, Fernandez-Luna JL, Real PJ, Tang H-Y, et al. Proximity labeling identifies a repertoire of site-specific R-loop modulators. Nat Commun. 2022;13:53. https://doi.org/10.1038/s41467-021-27722-6.
Article CAS PubMed Central PubMed Google Scholar
Pavri R. R loops in the regulation of antibody gene diversification. Genes (Basel). 2017. https://doi.org/10.3390/genes8060154.
Article PubMed Central PubMed Google Scholar
Mackay RP, Xu Q, Weinberger PM. R-loop physiology and pathology: a brief review. DNA Cell Biol. 2020;39:1914–25. https://doi.org/10.1089/dna.2020.5906.
Article CAS PubMed Google Scholar
Sahu RK, Singh S, Tomar RS. The ATP-dependent SWI/SNF and RSC chromatin remodelers cooperatively induce unfolded protein response genes during endoplasmic reticulum stress. Biochim Biophys Acta Gene Regul Mech. 2021;1864:194748. https://doi.org/10.1016/j.bbagrm.2021.194748.
Article CAS PubMed Google Scholar
Walker C, Burggren W. Remodeling the epigenome and (epi)cytoskeleton: a new paradigm for co-regulation by methylation. J Exp Biol. 2020. https://doi.org/10.1242/jeb.220632.
Article PubMed Central PubMed Google Scholar
Griesi-Oliveira K, Suzuki AM, Alves AY, Mafra ACCN, Yamamoto GL, Ezquina S, et al. Actin cytoskeleton dynamics in stem cells from autistic individuals. Sci Rep. 2018;8:11138. https://doi.org/10.1038/s41598-018-29309-6.
Article CAS PubMed Central PubMed Google Scholar
Yokoyama H. Chromatin-binding proteins moonlight as mitotic microtubule regulators. Trends Cell Biol. 2016;26:161–4. https://doi.org/10.1016/j.tcb.2015.12.005.
Article CAS PubMed Google Scholar
Reis LM, Tyler RC, Weh E, Hendee KE, Schilter KF, Phillips JA, et al. Whole exome sequencing identifies multiple diagnoses in congenital glaucoma with systemic anomalies. Clin Genet. 2016;90:378–82. https://doi.org/10.1111/cge.12816.
Article CAS PubMed Central PubMed Google Scholar
Forés-Martos J, Catalá-López F, Sánchez-Valle J, Ibáñez K, Tejero H, Palma-Gudiel H, et al. Transcriptomic metaanalyses of autistic brains reveals shared gene expression and biological pathway abnormalities with cancer. Mol Autism. 2019;10:17. https://doi.org/10.1186/s13229-019-0262-8.
Article PubMed Central PubMed Google Scholar
Hochedlinger K, Blelloch R, Brennan C, Yamada Y, Kim M, Chin L, et al. Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev. 2004;18:1875–85. https://doi.org/10.1101/gad.1213504.
Article CAS PubMed Central PubMed Google Scholar
Kim J, Zaret KS. Reprogramming of human cancer cells to pluripotency for models of cancer progression. EMBO J. 2015;34:739–47. https://doi.org/10.15252/embj.201490736.
Article CAS PubMed Central PubMed Google Scholar
Weng Q, Wang J, Wang J, He D, Cheng Z, Zhang F, et al. Single-cell transcriptomics uncovers glial progenitor diversity and cell fate determinants during development and gliomagenesis. Cell Stem Cell. 2019;24:707-723.e8. https://doi.org/10.1016/j.stem.2019.03.006.
Article CAS PubMed Central PubMed Google Scholar
Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell. 2019;178:835-849.e21. https://doi.org/10.1016/j.cell.2019.06.024.
Article CAS PubMed Central PubMed Google Scholar
Arai Y, Taverna E. Neural progenitor cell polarity and cortical development. Front Cell Neurosci. 2017;11:384. https://doi.org/10.3389/fncel.2017.00384.
Article CAS PubMed Central PubMed Google Scholar
Kalcheim C. Epithelial-mesenchymal transitions during neural crest and somite development. J Clin Med. 2015. https://doi.org/10.3390/jcm5010001.
Article PubMed Central PubMed Google Scholar
Plygawko AT, Kan S, Campbell K. Epithelial-mesenchymal plasticity: emerging parallels between tissue morphogenesis and cancer metastasis. Philos Trans R Soc Lond B, Biol Sci. 2020;375:20200087. https://doi.org/10.1098/rstb.2020.0087.
Article CAS PubMed Google Scholar
Thornton CA, Mulqueen RM, Torkenczy KA, Nishida A, Lowenstein EG, Fields AJ, et al. Spatially mapped single-cell chromatin accessibility. Nat Commun. 2021;12:1274. https://doi.org/10.1038/s41467-021-21515-7.
Article CAS PubMed Central PubMed Google Scholar
Yu M, Abnousi A, Zhang Y, Li G, Lee L, Chen Z, et al. SnapHiC: a computational pipeline to identify chromatin loops from single-cell Hi-C data. Nat Methods. 2021;18:1056–9. https://doi.org/10.1038/s41592-021-01231-2.
Article CAS PubMed Central PubMed Google Scholar
Winick-Ng W, Kukalev A, Harabula I, Zea-Redondo L, Szabó D, Meijer M, et al. Cell-type specialization is encoded by specific chromatin topologies. Nature. 2021;599:684–91. https://doi.org/10.1038/s41586-021-04081-2.
Article CAS PubMed Central PubMed Google Scholar
Cardozo Gizzi AM. A shift in paradigms: spatial genomics approaches to reveal single-cell principles of genome organization. Front Genet. 2021;12:780822. https://doi.org/10.3389/fgene.2021.780822.
Article CAS PubMed Central PubMed Google Scholar
Kaya-Okur HS, Wu SJ, Codomo CA, Pledger ES, Bryson TD, Henikoff JG, et al. CUT&Tag for efficient epigenomic profiling of small samples and single cells. Nat Commun. 2019;10:1930. https://doi.org/10.1038/s41467-019-09982-5.
Article CAS PubMed Central PubMed Google Scholar
Yim YY, Teague CD, Nestler EJ. In vivo locus-specific editing of the neuroepigenome. Nat Rev Neurosci. 2020;21:471–84. https://doi.org/10.1038/s41583-020-0334-y.
Article CAS PubMed Central PubMed Google Scholar
Liu XS, Jaenisch R. Editing the epigenome to tackle brain disorders. Trends Neurosci. 2019;42:861–70. https://doi.org/10.1016/j.tins.2019.10.003.
Article CAS PubMed Google Scholar
Thorn GJ, Clarkson CT, Rademacher A, Mamayusupova H, Schotta G, Rippe K, et al. DNA sequence-dependent formation of heterochromatin nanodomains. Nat Commun. 2022;13:1861. https://doi.org/10.1038/s41467-022-29360-y.
Article CAS PubMed Central PubMed Google Scholar
Singh PB, Newman AG. HP1-driven micro-phase separation of heterochromatin-like domains/complexes. Epigenet Insights. 2022;15:25168657221109770. https://doi.org/10.1177/25168657221109766.
Article PubMed Central PubMed Google Scholar
Hashimoto H, Wang D, Horton JR, Zhang X, Corces VG, Cheng X. Structural basis for the versatile and methylation-dependent binding of CTCF to DNA. Mol Cell. 2017;66:711-720.e3. https://doi.org/10.1016/j.molcel.2017.05.004.
Article CAS PubMed Central PubMed Google Scholar

Download references

Acknowledgements

The authors thank Christopher Pearson for helpful suggestions regarding the manuscript.

Funding

This article is based upon work from COST Action International Nucleome Consortium (INC) CA18127, supported by COST (European Cooperation in Science and Technology) (WVB) and supported by grants from the European Research Area Networks Network of European Funding ERA-NET AUTISYN and ADNPinMED (IG, GT and RFK) and E-Rare IMPACT (GT, RFK). The authors acknowledge the support of the Research Fund of the University of Antwerp OEC-Methusalem grant ‘GENOMED’ to RFK, the OEC IPPON.

Author information

Claudio Peter D’Incal and Kirsten Van Rossem contributed equally to this work

Authors and Affiliations

Department of Medical Genetics, University of Antwerp, Prins Boudewijnlaan 43/6, 2650, Edegem, Belgium
Claudio Peter D’Incal, Kirsten Esther Van Rossem, Anke Van Dijck & R. Frank Kooy
Protein Chemistry, Proteomics and Epigenetic Signaling (PPES), Epigenetic Signaling Lab (PPES), Department of Biomedical Sciences, University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium
Claudio Peter D’Incal, Kevin De Man, Anthony Konings & Wim Vanden Berghe
High Definition Disease Modelling Lab, Stem Cell and Organoid Epigenetics, IEO, European Institute of Oncology, IRCCS, 20141, Milan, Italy
Ludovico Rizzuti, Alessandro Vitriolo & Giuseppe Testa
Department of Oncology and Hemato-Oncology, University of Milan, 20122, Milan, Italy
Ludovico Rizzuti, Alessandro Vitriolo & Giuseppe Testa
Human Technopole, V. Le Rita Levi-Montalcini, 1, 20157, Milan, Italy
Ludovico Rizzuti, Alessandro Vitriolo & Giuseppe Testa
Elton Laboratory for Molecular Neuroendocrinology, Department of Human Molecular Genetics and Biochemistry, Faculty of Medicine, Adams Super Center for Brain Studies and Sagol School of Neuroscience, Tel Aviv University, Sackler School of Medicine, 727, 69978, Tel Aviv, Israel
Illana Gozes

Authors

Claudio Peter D’Incal
View author publications
You can also search for this author in PubMed Google Scholar
Kirsten Esther Van Rossem
View author publications
You can also search for this author in PubMed Google Scholar
Kevin De Man
View author publications
You can also search for this author in PubMed Google Scholar
Anthony Konings
View author publications
You can also search for this author in PubMed Google Scholar
Anke Van Dijck
View author publications
You can also search for this author in PubMed Google Scholar
Ludovico Rizzuti
View author publications
You can also search for this author in PubMed Google Scholar
Alessandro Vitriolo
View author publications
You can also search for this author in PubMed Google Scholar
Giuseppe Testa
View author publications
You can also search for this author in PubMed Google Scholar
Illana Gozes
View author publications
You can also search for this author in PubMed Google Scholar
Wim Vanden Berghe
View author publications
You can also search for this author in PubMed Google Scholar
R. Frank Kooy
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

CD, KVR, WVDB, and RFK contributed to conceptualization; CD, KVR, WVDB, and RFK were involved in methodology; CD, KVR, AVD, LR, AV, GT, IG, WVDB, and RFK contributed to writing—original draft preparation; CD, IG, WVB, and RFK were involved in writing—review and editing; CD, KDM, and AK contributed to visualization; and all authors have read and agreed to the published version of the manuscript.

Corresponding authors

Correspondence to Wim Vanden Berghe or R. Frank Kooy.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Competing interests

The authors declare no conflict of interest. Professor Illana Gozes is a Co-Founder, Chief Scientific Officer and a Director at ATED Therapeutics, clinically developing davunetide.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Cite this article

D’Incal, C.P., Van Rossem, K.E., De Man, K. et al. Chromatin remodeler Activity-Dependent Neuroprotective Protein (ADNP) contributes to syndromic autism. Clin Epigenet 15, 45 (2023). https://doi.org/10.1186/s13148-023-01450-8

Download citation

Received: 22 December 2022
Accepted: 16 February 2023
Published: 21 March 2023
DOI: https://doi.org/10.1186/s13148-023-01450-8

Chromatin remodeler Activity-Dependent Neuroprotective Protein (ADNP) contributes to syndromic autism

Abstract

Background

Results

Conclusions

Introduction

ADNP is an embryonic gene essential for brain formation

ADNP is a highly conserved chordate-specific gene that only shows homology with its paralogue Activity-Dependent Neuroprotective 2 gene (ADNP2)

ADNP in neurodevelopment

Mutations in ADNP result in Helsmoortel–Van der Aa syndrome (HVDAS)

The role of mosaicism in patients

Opposing epigenetic signatures of the Helsmoortel–Van der Aa syndrome

ADNP interacts with multiple chromatin remodeling proteins complexes

Interaction with SWI/SNF complex

ADNP is part of the ChAHP complex

ADNP-BRG1-CHD4 (ABC) triplex

The nuclear ADNP-HP1-POGZ complex

ADNP-WDR5-SIRT1-BRG1-HDAC2 including YY1 complex

ADNP regulates microtubule functions

Autism-mutated ADNP plays a pivotal role in autophagy by affecting cytoskeleton dynamics

ADNP and its regulating neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) protect neurons against stress

The NAP motif in ADNP

NAP and microtubules

The ADNP, NAP, and Tau interaction

Candidate drugs for the Helsmoortel–Van der Aa syndrome

ADNP dysregulation in cancer development

ADNP chromatinopathies disturb higher-order 3D chromatin landscapes

A concluding look ahead

Availability of data and materials

Institutional review board statement

Change history

01 January 2024

References

Acknowledgements

Funding

Author information

Authors and Affiliations

Contributions

Corresponding authors

Ethics declarations

Ethics approval and consent to participate

Competing interests

Additional information

Publisher's Note

Rights and permissions

About this article

Cite this article

Share this article

Keywords

Clinical Epigenetics

Contact us